This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-139-5p | AKT3 | -1.46 | 0 | 0.76 | 5.0E-5 | PITA; miRanda | -0.2 | 7.0E-5 | NA | |
2 | hsa-miR-15a-5p | AKT3 | 0.78 | 0 | 0.76 | 5.0E-5 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.27 | 0.00011 | NA | |
3 | hsa-miR-17-5p | AKT3 | 1.42 | 0 | 0.76 | 5.0E-5 | TargetScan; miRNATAP | -0.21 | 1.0E-5 | NA | |
4 | hsa-miR-205-3p | AKT3 | 1.3 | 0 | 0.76 | 5.0E-5 | mirMAP | -0.25 | 0 | NA | |
5 | hsa-miR-20a-5p | AKT3 | 1.15 | 0 | 0.76 | 5.0E-5 | miRNATAP | -0.24 | 0 | NA | |
6 | hsa-miR-29b-3p | AKT3 | -0.11 | 0.51126 | 0.76 | 5.0E-5 | miRNATAP | -0.26 | 0 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
7 | hsa-miR-362-3p | AKT3 | -0.7 | 0 | 0.76 | 5.0E-5 | miRanda | -0.2 | 0.00031 | NA | |
8 | hsa-miR-362-5p | AKT3 | 0.41 | 0.04043 | 0.76 | 5.0E-5 | PITA; TargetScan; miRNATAP | -0.16 | 0.00012 | NA | |
9 | hsa-miR-127-3p | BAD | -1.47 | 0 | 0.23 | 0.0411 | miRanda; miRNATAP | -0.11 | 1.0E-5 | NA | |
10 | hsa-miR-326 | BAD | -0.43 | 0.0415 | 0.23 | 0.0411 | miRanda | -0.16 | 0 | NA | |
11 | hsa-miR-193b-3p | CASP9 | 1.73 | 0 | -0.46 | 0 | miRNAWalker2 validate | -0.15 | 0 | NA | |
12 | hsa-miR-424-5p | CASP9 | 1.48 | 0 | -0.46 | 0 | mirMAP | -0.14 | 0 | NA | |
13 | hsa-miR-7-5p | CASP9 | 1.56 | 0 | -0.46 | 0 | miRNAWalker2 validate | -0.1 | 0 | NA | |
14 | hsa-miR-106b-5p | CDC42 | 0.5 | 1.0E-5 | 0.01 | 0.84641 | miRNAWalker2 validate | -0.13 | 0 | NA | |
15 | hsa-miR-107 | CDC42 | -0.04 | 0.67162 | 0.01 | 0.84641 | miRanda | -0.13 | 0 | 23627613 | Quantitative real-time PCR was used to analyze the expression of miR-107 and its bioinformatically identified targets PIM-1 and CDC42 |
16 | hsa-miR-28-3p | CDC42 | 0.46 | 0 | 0.01 | 0.84641 | PITA | -0.13 | 7.0E-5 | NA | |
17 | hsa-let-7a-5p | HRAS | -0.44 | 3.0E-5 | 0.26 | 0.05562 | miRNAWalker2 validate; miRTarBase | -0.3 | 0 | 20607356; 23134218; 18344688; 20033209; 19323605 | Transfection of let-7 miRNA reduced expression of pan-RAS N-RAS and K-RAS in the glioblastoma cells;MicroRNA let 7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K Ras and HMGA2 gene expression; K-RAS and HMGA2 mRNA levels were significantly higher in the let-7a overexpressed group than those in the let-7a inhibited group p < 0.05; However the protein levels of K-RAS and HMGA2 were significantly lower in the let-7a overexpressed group than those in the let-7a inhibited group p < 0.05; We suppose that let-7a inhibits the proliferation and invasion of the cell line 95D by regulating the translation of K-RAS and HMGA2 mRNA not the transcription of the mRNA itself;Using an established orthotopic mouse lung cancer model we show that intranasal let-7 administration reduces tumor formation in vivo in the lungs of animals expressing a G12D activating mutation for the K-ras oncogene;k-Ras and c-Myc two key oncogenes in lung cancer have been found to be targeted by let-7 in vitro; The aim of the present study is to determine the effect of let-7a a member of let-7 family on the growth of lung cancer in vivo and to investigate whether let-7-induced suppression of k-Ras and c-Myc is involved in lung cancer; Overexpression of let-7a can inhibit the growth of lung cancer transplanted subcutaneously in nude mice by suppression of k-Ras and c-Myc;Because let-7 microRNA targets the K-ras oncogene we aimed to characterize let-7 expression and function in PDAC in vitro and in vivo; Restoring let-7 levels in cancer-derived cell lines strongly inhibits cell proliferation K-ras expression and mitogen-activated protein kinase activation but fails to impede tumor growth progression after intratumoral gene transfer or after implantation of Capan-1 cells stably overexpressing let-7 microRNA |
18 | hsa-let-7b-5p | HRAS | -0.25 | 0.02114 | 0.26 | 0.05562 | miRTarBase | -0.22 | 0.0001 | 20607356; 20881268; 18344688; 20033209; 19323605 | Transfection of let-7 miRNA reduced expression of pan-RAS N-RAS and K-RAS in the glioblastoma cells;On the basis of these data we suggest that the downregulation of let-7b and let-7e targeting K-ras and the upregulation of miR-17* a CRC marker could be considered as candidate molecular markers of cetuximab resistance;Using an established orthotopic mouse lung cancer model we show that intranasal let-7 administration reduces tumor formation in vivo in the lungs of animals expressing a G12D activating mutation for the K-ras oncogene;k-Ras and c-Myc two key oncogenes in lung cancer have been found to be targeted by let-7 in vitro; The aim of the present study is to determine the effect of let-7a a member of let-7 family on the growth of lung cancer in vivo and to investigate whether let-7-induced suppression of k-Ras and c-Myc is involved in lung cancer;Because let-7 microRNA targets the K-ras oncogene we aimed to characterize let-7 expression and function in PDAC in vitro and in vivo; Restoring let-7 levels in cancer-derived cell lines strongly inhibits cell proliferation K-ras expression and mitogen-activated protein kinase activation but fails to impede tumor growth progression after intratumoral gene transfer or after implantation of Capan-1 cells stably overexpressing let-7 microRNA |
19 | hsa-miR-143-3p | HRAS | -1.34 | 0 | 0.26 | 0.05562 | miRNAWalker2 validate; miRTarBase | -0.25 | 0 | 21276449 | The Evi1 microRNA 143 K Ras axis in colon cancer |
20 | hsa-miR-181d-5p | HRAS | 0.37 | 0.00537 | 0.26 | 0.05562 | miRNAWalker2 validate; miRTarBase | -0.12 | 0.00678 | NA | |
21 | hsa-miR-330-5p | JMJD7-PLA2G4B | 0.94 | 0 | -0.8 | 0 | miRNATAP | -0.19 | 0.00036 | NA | |
22 | hsa-miR-542-3p | JMJD7-PLA2G4B | 0.64 | 0 | -0.8 | 0 | miRNATAP | -0.32 | 0 | NA | |
23 | hsa-miR-149-5p | KDR | 0.44 | 0.0642 | -0.06 | 0.72302 | miRNATAP | -0.16 | 0 | NA | |
24 | hsa-miR-15a-5p | KDR | 0.78 | 0 | -0.06 | 0.72302 | miRNATAP | -0.54 | 0 | NA | |
25 | hsa-miR-15b-5p | KDR | 0.85 | 0 | -0.06 | 0.72302 | miRNATAP | -0.23 | 0.00023 | NA | |
26 | hsa-miR-16-5p | KDR | 0.52 | 0 | -0.06 | 0.72302 | miRTarBase; miRNATAP | -0.25 | 0.00053 | 26934556 | The expression levels of two target genes Myb and VEGFR2 were affected significantly by miR-16 while glucose administration inhibited miR-16 expression and enhanced tumor cell proliferation and migration; Hyperglycemia can impact the clinical outcomes of CRC patients likely by inhibiting miR-16 expression and the expression of its downstream genes Myb and VEGFR2 |
27 | hsa-miR-19b-1-5p | KDR | 0.76 | 0 | -0.06 | 0.72302 | miRNAWalker2 validate | -0.4 | 0 | NA | |
28 | hsa-miR-200b-3p | KDR | 0.07 | 0.68286 | -0.06 | 0.72302 | miRNAWalker2 validate; miRTarBase; TargetScan | -0.26 | 0 | NA | |
29 | hsa-miR-200c-3p | KDR | 0.63 | 0.00013 | -0.06 | 0.72302 | miRNATAP | -0.26 | 0 | 24205206 | MiR 200c increases the radiosensitivity of non small cell lung cancer cell line A549 by targeting VEGF VEGFR2 pathway; MiR-200c at the nexus of epithelial-mesenchymal transition EMT is predicted to target VEGFR2; The purpose of this study is to test the hypothesis that regulation of VEGFR2 pathway by miR-200c could modulate the radiosensitivity of cancer cells; Bioinformatic analysis luciferase reporter assays and biochemical assays were carried out to validate VEGFR2 as a direct target of miR-200c; We identified VEGFR2 as a novel target of miR-200c |
30 | hsa-miR-338-3p | KDR | -0.95 | 0 | -0.06 | 0.72302 | PITA; miRanda | -0.2 | 0 | NA | |
31 | hsa-miR-429 | KDR | 0.56 | 0.00564 | -0.06 | 0.72302 | PITA; miRanda; miRNATAP | -0.27 | 0 | NA | |
32 | hsa-miR-455-5p | KDR | 1.41 | 0 | -0.06 | 0.72302 | PITA; miRanda; miRNATAP | -0.28 | 0 | NA | |
33 | hsa-miR-590-3p | KDR | 0.22 | 0.09659 | -0.06 | 0.72302 | miRanda | -0.17 | 0.0041 | NA | |
34 | hsa-miR-590-5p | KDR | 0.76 | 0 | -0.06 | 0.72302 | miRanda | -0.42 | 0 | NA | |
35 | hsa-miR-664a-3p | KDR | -0.26 | 0.05132 | -0.06 | 0.72302 | mirMAP | -0.19 | 0.00135 | NA | |
36 | hsa-let-7a-3p | KRAS | 0.1 | 0.42376 | -0.04 | 0.6721 | mirMAP; miRNATAP | -0.14 | 0.00014 | 24727325; 20603437; 24890702; 23324806; 21994416; 23167843; 27620744; 20177422; 25183481; 22584434; 18922928 | Association study of the let 7 miRNA complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer NCCTG N0147 Clinical Trial; A let-7 microRNA-complementary site LCS6 polymorphism in the 3' untranslated region of the KRAS gene has been shown to disrupt let-7 binding and upregulate KRAS expression;A let 7 microRNA binding site polymorphism in 3' untranslated region of KRAS gene predicts response in wild type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy; A polymorphism in a let-7 microRNA complementary site lcs6 in the KRAS 3' untranslated region UTR is associated with an increased cancer risk in non-small-cell lung cancer and reduced overall survival OS in oral cancers; the presence of KRAS let-7 lcs6 polymorphism was evaluated in 130 mCRC patients who were enrolled in a phase II study of cetuximab monotherapy IMCL-0144; KRAS let-7 lcs6 polymorphism was found to be related to object response rate ORR in mCRC patients whose tumors had KRASwt;Let 7 microRNA binding site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta analysis; There is a small but growing body of literature regarding the predictive utility of a Let-7 microRNA-binding-site polymorphism in the 3'-untranslated region UTR of KRAS KRAS-LCS6 for colorectal cancer outcome although the results are conflicting; A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism LCS6; rs61764370 and colorectal cancer outcome;The LCS6 polymorphism in the binding site of let 7 microRNA to the KRAS 3' untranslated region: its role in the efficacy of anti EGFR based therapy in metastatic colorectal cancer patients; The lethal-7 let-7 family of microRNAs regulates KRAS activity; We studied the association of the KRAS let-7 LCS6 polymorphism with the response in 100 refractory mCRC patients treated with anti-EGFR antibodies; The KRAS let-7 LCS6 polymorphism was genotyped using the BioMark system in blood and tumor DNA samples; The KRAS let-7 LCS6 G-allele showed a statistically significant association with nonresponse to anti-EGFR-based treatment: 31.9% of patients with the T/T genotype presented a complete or a partial response versus no patients with T/G or G/G genotypes P=0.004;A let 7 microRNA SNP in the KRAS 3'UTR is prognostic in early stage colorectal cancer; Recently a SNP in a lethal-7 let-7 miRNA complementary site LCS6 in the KRAS 3'untranslated region was suggested to affect survival in metastatic CRC;Let 7 miRNA binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5 fluorouracil and oxaliplatin +/ cetuximab; Recent studies have reported associations between a variant allele in a let-7 microRNA complementary site LCS6 within the 3'untranslated region 3'UTR of KRAS rs61764370 and clinical outcome in metastatic colorectal cancer mCRC patients receiving cetuximab;A let 7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population; The let-7 microRNAs play a key role in regulating KRAS expression and a polymorphism in 3' untranslated region rs61764370 T/G of KRAS leads to its higher expression;Genetic modulation of the Let 7 microRNA binding to KRAS 3' untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab irinotecan; There is increasing evidence that the Let-7 microRNA miRNA exerts an effect as a tumor suppressor by targeting the KRAS mRNA; The Let-7 complementary site LCS6 T>G variant in the KRAS 3'-untranslated region weakens Let-7 binding;A let 7 microRNA binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy;High let 7a microRNA levels in KRAS mutated colorectal carcinomas may rescue anti EGFR therapy effects in patients with chemotherapy refractory metastatic disease; Preclinical and experimental data in vivo indicate that Lethal-7 Let-7 microRNA downregulates KRAS with antitumor effects in the presence of activating KRAS mutations; In 59 patients harboring KRAS mutations Let-7a levels were analyzed for association with overall survival OS and progression-free survival PFS times; An exploratory subgroup analysis was performed using the rs61764370 LCS6 T>G polymorphism that experimentally impairs Let-7 binding to KRAS mRNA; In patients with KRAS mutations Let-7a analysis may serve to identify subgroups of patients who may still benefit from EGFR inhibition and this may open up new perspectives for alternative treatment strategies;A SNP in a let 7 microRNA complementary site in the KRAS 3' untranslated region increases non small cell lung cancer risk; The purpose of this study was to identify single nucleotide polymorphisms SNP that could modify let-7 binding and to assess the effect of such SNPs on target gene regulation and risk for non-small cell lung cancer NSCLC let-7 complementary sites LCS were sequenced in the KRAS 3' untranslated region from 74 NSCLC cases to identify mutations and SNPs that correlated with NSCLC; The LCS6 variant allele in a KRAS miRANA complementary site is significantly associated with increased risk for NSCLC among moderate smokers and represents a new paradigm for let-7 miRNAs in lung cancer susceptibility |
37 | hsa-miR-126-3p | KRAS | 0.05 | 0.73013 | -0.04 | 0.6721 | miRNAWalker2 validate; miRTarBase | -0.12 | 0.00015 | 22845403 | miR-126 is also known to target other crucial oncogenes in PDAC such as KRAS and CRK |
38 | hsa-miR-155-5p | KRAS | 0.53 | 0.00249 | -0.04 | 0.6721 | miRNAWalker2 validate; miRNATAP | -0.11 | 1.0E-5 | NA | |
39 | hsa-miR-181a-5p | KRAS | 0.82 | 0 | -0.04 | 0.6721 | miRNAWalker2 validate | -0.21 | 0 | 24098024; 27517749; 26124189 | The KRAS mutational status was determined by pyrosequencing and miR-181a expression was measured by quantitative RT-PCR in CRC tumour tissue and corresponding non-neoplastic colon tissue;Here we report that miR-181a directly binds to 3'-untranslated regions UTRs; downregulates KRAS NRAS and MAPK1; and decreases AML growth; The delivery of miR-181a mimics to target AML cells using transferrin-targeting lipopolyplex nanoparticles NP increased mature miR-181a; downregulated KRAS NRAS and MAPK1; and resulted in decreased phosphorylation of the downstream RAS effectors;MiR 181a 5p inhibits cell proliferation and migration by targeting Kras in non small cell lung cancer A549 cells; Luciferase activity assay results demonstrated that two binding sites of Kras could be directly targeted by miR-181a-5p; Furthermore Kras was down-regulated by miR-181a-5p at both transcriptional and translational levels; SiRNA-mediated Kras down-regulation could mimic the effects of miR-181a-5p mimic in A549 cells; Our findings suggest that miR-181a-5p plays a potential role in tumor suppression by partially targeting Kras and has the potential therapeutic application in NSCLC patients |
40 | hsa-miR-186-5p | KRAS | 0.35 | 0.00015 | -0.04 | 0.6721 | mirMAP | -0.21 | 1.0E-5 | NA | |
41 | hsa-miR-30a-5p | KRAS | -1.8 | 0 | -0.04 | 0.6721 | mirMAP; miRNATAP | -0.11 | 1.0E-5 | NA | |
42 | hsa-miR-30b-5p | KRAS | -0.4 | 0.00347 | -0.04 | 0.6721 | mirMAP; miRNATAP | -0.15 | 0 | NA | |
43 | hsa-miR-30c-5p | KRAS | 0.02 | 0.88637 | -0.04 | 0.6721 | mirMAP; miRNATAP | -0.16 | 0 | 22701724 | Deregulated miRNAs in hereditary breast cancer revealed a role for miR 30c in regulating KRAS oncogene; In particular we experimentally validated KRAS as a miR-30c target; Luciferase assays confirmed that miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein; In addition we provide evidence that KRAS is a target of miR-30c and that this miRNA suppresses breast cancer cell growth potentially through inhibition of KRAS signaling |
44 | hsa-miR-501-3p | KRAS | 0.82 | 0 | -0.04 | 0.6721 | MirTarget; PITA; TargetScan; miRNATAP | -0.11 | 0.00026 | NA | |
45 | hsa-miR-542-3p | KRAS | 0.64 | 0 | -0.04 | 0.6721 | miRanda | -0.14 | 3.0E-5 | NA | |
46 | hsa-miR-30c-5p | MAP2K1 | 0.02 | 0.88637 | 0.14 | 0.05904 | miRNAWalker2 validate | -0.11 | 0 | NA | |
47 | hsa-miR-34a-5p | MAP2K1 | -0.12 | 0.364 | 0.14 | 0.05904 | miRNAWalker2 validate; miRTarBase | -0.12 | 0 | NA | |
48 | hsa-let-7b-5p | MAP2K2 | -0.25 | 0.02114 | -0.14 | 0.11731 | miRNAWalker2 validate | -0.23 | 0 | NA | |
49 | hsa-miR-130a-3p | MAPK1 | 0.67 | 0 | -0.03 | 0.75566 | mirMAP | -0.12 | 0 | NA | |
50 | hsa-miR-140-5p | MAPK1 | -0.41 | 0.00014 | -0.03 | 0.75566 | miRanda | -0.11 | 0.00107 | NA | |
51 | hsa-miR-16-2-3p | MAPK1 | 1.16 | 0 | -0.03 | 0.75566 | mirMAP | -0.12 | 0 | NA | |
52 | hsa-miR-19a-3p | MAPK1 | 1.36 | 0 | -0.03 | 0.75566 | mirMAP | -0.11 | 0 | NA | |
53 | hsa-miR-19b-3p | MAPK1 | 0.54 | 0.00062 | -0.03 | 0.75566 | mirMAP | -0.15 | 0 | NA | |
54 | hsa-miR-24-1-5p | MAPK1 | -0.05 | 0.74286 | -0.03 | 0.75566 | mirMAP | -0.12 | 0 | NA | |
55 | hsa-miR-29a-5p | MAPK1 | 0.32 | 0.03704 | -0.03 | 0.75566 | mirMAP | -0.1 | 1.0E-5 | NA | |
56 | hsa-miR-29b-2-5p | MAPK1 | -0.5 | 0.00073 | -0.03 | 0.75566 | mirMAP | -0.14 | 0 | NA | |
57 | hsa-miR-29b-3p | MAPK1 | -0.11 | 0.51126 | -0.03 | 0.75566 | mirMAP | -0.16 | 0 | NA | |
58 | hsa-miR-30b-5p | MAPK1 | -0.4 | 0.00347 | -0.03 | 0.75566 | mirMAP | -0.17 | 0 | NA | |
59 | hsa-miR-30c-5p | MAPK1 | 0.02 | 0.88637 | -0.03 | 0.75566 | mirMAP | -0.17 | 0 | NA | |
60 | hsa-miR-30d-3p | MAPK1 | -0.58 | 0 | -0.03 | 0.75566 | mirMAP | -0.12 | 2.0E-5 | NA | |
61 | hsa-miR-32-5p | MAPK1 | -0.32 | 0.01025 | -0.03 | 0.75566 | mirMAP | -0.12 | 3.0E-5 | NA | |
62 | hsa-miR-320a | MAPK1 | 0.8 | 0 | -0.03 | 0.75566 | miRNAWalker2 validate; PITA; miRanda; miRNATAP | -0.13 | 0 | NA | |
63 | hsa-miR-338-3p | MAPK1 | -0.95 | 0 | -0.03 | 0.75566 | miRanda | -0.13 | 0 | NA | |
64 | hsa-miR-342-3p | MAPK1 | 1 | 0 | -0.03 | 0.75566 | miRanda; mirMAP | -0.17 | 0 | NA | |
65 | hsa-miR-34a-5p | MAPK1 | -0.12 | 0.364 | -0.03 | 0.75566 | mirMAP | -0.23 | 0 | NA | |
66 | hsa-miR-362-3p | MAPK1 | -0.7 | 0 | -0.03 | 0.75566 | mirMAP | -0.11 | 0 | NA | |
67 | hsa-miR-362-5p | MAPK1 | 0.41 | 0.04043 | -0.03 | 0.75566 | mirMAP | -0.14 | 0 | NA | |
68 | hsa-miR-374a-3p | MAPK1 | -0.3 | 0.00683 | -0.03 | 0.75566 | mirMAP | -0.11 | 0.00057 | NA | |
69 | hsa-miR-374b-5p | MAPK1 | -0.29 | 0.00415 | -0.03 | 0.75566 | mirMAP | -0.19 | 0 | NA | |
70 | hsa-miR-454-3p | MAPK1 | 1.54 | 0 | -0.03 | 0.75566 | mirMAP | -0.13 | 0 | NA | |
71 | hsa-miR-500a-3p | MAPK1 | 0.46 | 0.00069 | -0.03 | 0.75566 | mirMAP | -0.18 | 0 | NA | |
72 | hsa-miR-501-3p | MAPK1 | 0.82 | 0 | -0.03 | 0.75566 | mirMAP | -0.11 | 0 | NA | |
73 | hsa-miR-501-5p | MAPK1 | 1.03 | 0 | -0.03 | 0.75566 | mirMAP | -0.1 | 0 | NA | |
74 | hsa-miR-502-3p | MAPK1 | -0.17 | 0.10688 | -0.03 | 0.75566 | mirMAP | -0.12 | 0.00064 | NA | |
75 | hsa-miR-505-3p | MAPK1 | 0.91 | 0 | -0.03 | 0.75566 | mirMAP | -0.11 | 4.0E-5 | NA | |
76 | hsa-miR-660-5p | MAPK1 | -0.2 | 0.10109 | -0.03 | 0.75566 | mirMAP | -0.2 | 0 | NA | |
77 | hsa-let-7a-5p | MAPK11 | -0.44 | 3.0E-5 | 0.66 | 0 | miRNAWalker2 validate | -0.23 | 7.0E-5 | NA | |
78 | hsa-miR-140-3p | MAPK11 | -0.97 | 0 | 0.66 | 0 | mirMAP | -0.18 | 0.00205 | NA | |
79 | hsa-miR-125a-3p | MAPK13 | 0.12 | 0.44483 | -0.51 | 0.0007 | miRanda | -0.2 | 1.0E-5 | NA | |
80 | hsa-miR-320a | MAPK14 | 0.8 | 0 | -0.1 | 0.17305 | PITA; miRanda | -0.11 | 0 | NA | |
81 | hsa-miR-320b | MAPK3 | 1.23 | 0 | -0.86 | 0 | miRNAWalker2 validate | -0.15 | 0 | NA | |
82 | hsa-miR-34a-5p | MAPK3 | -0.12 | 0.364 | -0.86 | 0 | miRNAWalker2 validate | -0.14 | 1.0E-5 | NA | |
83 | hsa-miR-423-3p | MAPK3 | 1.2 | 0 | -0.86 | 0 | miRNAWalker2 validate | -0.11 | 0.00069 | NA | |
84 | hsa-miR-423-5p | MAPK3 | 0.6 | 0 | -0.86 | 0 | miRNATAP | -0.16 | 0 | NA | |
85 | hsa-miR-542-3p | MAPK3 | 0.64 | 0 | -0.86 | 0 | miRanda | -0.11 | 0.00048 | NA | |
86 | hsa-miR-421 | MAPKAPK3 | 0.95 | 0 | -1.17 | 0 | miRanda | -0.11 | 0.0004 | NA | |
87 | hsa-miR-429 | MAPKAPK3 | 0.56 | 0.00564 | -1.17 | 0 | miRNATAP | -0.14 | 0 | NA | |
88 | hsa-miR-103a-3p | NFAT5 | 0.56 | 0 | -0.14 | 0.16169 | MirTarget | -0.21 | 2.0E-5 | NA | |
89 | hsa-miR-106b-5p | NFAT5 | 0.5 | 1.0E-5 | -0.14 | 0.16169 | MirTarget; miRNATAP | -0.15 | 0.00013 | NA | |
90 | hsa-miR-1301-3p | NFAT5 | 2.14 | 0 | -0.14 | 0.16169 | MirTarget | -0.13 | 0 | NA | |
91 | hsa-miR-130b-5p | NFAT5 | 1.77 | 0 | -0.14 | 0.16169 | MirTarget; miRNATAP | -0.1 | 9.0E-5 | NA | |
92 | hsa-miR-148b-5p | NFAT5 | 1.15 | 0 | -0.14 | 0.16169 | MirTarget | -0.12 | 1.0E-5 | NA | |
93 | hsa-miR-155-5p | NFAT5 | 0.53 | 0.00249 | -0.14 | 0.16169 | mirMAP; miRNATAP | -0.11 | 3.0E-5 | NA | |
94 | hsa-miR-15a-5p | NFAT5 | 0.78 | 0 | -0.14 | 0.16169 | MirTarget | -0.26 | 0 | NA | |
95 | hsa-miR-15b-5p | NFAT5 | 0.85 | 0 | -0.14 | 0.16169 | MirTarget | -0.18 | 0 | NA | |
96 | hsa-miR-16-1-3p | NFAT5 | 0.96 | 0 | -0.14 | 0.16169 | mirMAP | -0.15 | 0 | NA | |
97 | hsa-miR-16-5p | NFAT5 | 0.52 | 0 | -0.14 | 0.16169 | MirTarget | -0.15 | 0.00027 | NA | |
98 | hsa-miR-17-3p | NFAT5 | -0.01 | 0.90956 | -0.14 | 0.16169 | mirMAP | -0.1 | 0.00945 | NA | |
99 | hsa-miR-17-5p | NFAT5 | 1.42 | 0 | -0.14 | 0.16169 | miRNAWalker2 validate; MirTarget; TargetScan; miRNATAP | -0.11 | 2.0E-5 | NA | |
100 | hsa-miR-181a-5p | NFAT5 | 0.82 | 0 | -0.14 | 0.16169 | MirTarget; miRNATAP | -0.13 | 0.00092 | NA | |
101 | hsa-miR-181c-5p | NFAT5 | -0.17 | 0.19695 | -0.14 | 0.16169 | MirTarget; miRNATAP | -0.11 | 0.0013 | NA | |
102 | hsa-miR-186-5p | NFAT5 | 0.35 | 0.00015 | -0.14 | 0.16169 | MirTarget; mirMAP | -0.15 | 0.00173 | NA | |
103 | hsa-miR-194-5p | NFAT5 | -0.02 | 0.87294 | -0.14 | 0.16169 | miRNATAP | -0.14 | 2.0E-5 | NA | |
104 | hsa-miR-20a-5p | NFAT5 | 1.15 | 0 | -0.14 | 0.16169 | MirTarget; miRNATAP | -0.13 | 0 | NA | |
105 | hsa-miR-21-5p | NFAT5 | 1.62 | 0 | -0.14 | 0.16169 | miRNAWalker2 validate; mirMAP | -0.12 | 0.00238 | NA | |
106 | hsa-miR-25-3p | NFAT5 | 0.77 | 0 | -0.14 | 0.16169 | miRNATAP | -0.24 | 0 | NA | |
107 | hsa-miR-27b-5p | NFAT5 | 0.58 | 0.00018 | -0.14 | 0.16169 | miRNATAP | -0.1 | 0.00033 | NA | |
108 | hsa-miR-29b-3p | NFAT5 | -0.11 | 0.51126 | -0.14 | 0.16169 | MirTarget; miRNATAP | -0.14 | 0 | NA | |
109 | hsa-miR-30b-5p | NFAT5 | -0.4 | 0.00347 | -0.14 | 0.16169 | MirTarget; miRNATAP | -0.17 | 0 | NA | |
110 | hsa-miR-30c-5p | NFAT5 | 0.02 | 0.88637 | -0.14 | 0.16169 | MirTarget; miRNATAP | -0.16 | 0 | NA | |
111 | hsa-miR-32-5p | NFAT5 | -0.32 | 0.01025 | -0.14 | 0.16169 | miRNATAP | -0.12 | 0.00106 | NA | |
112 | hsa-miR-320a | NFAT5 | 0.8 | 0 | -0.14 | 0.16169 | mirMAP | -0.13 | 4.0E-5 | NA | |
113 | hsa-miR-361-3p | NFAT5 | 0.27 | 0.01479 | -0.14 | 0.16169 | MirTarget; PITA; miRNATAP | -0.16 | 8.0E-5 | NA | |
114 | hsa-miR-3613-5p | NFAT5 | 0.41 | 0.00535 | -0.14 | 0.16169 | miRNATAP | -0.11 | 0.00029 | NA | |
115 | hsa-miR-362-5p | NFAT5 | 0.41 | 0.04043 | -0.14 | 0.16169 | mirMAP | -0.15 | 0 | NA | |
116 | hsa-miR-374a-3p | NFAT5 | -0.3 | 0.00683 | -0.14 | 0.16169 | mirMAP | -0.2 | 0 | NA | |
117 | hsa-miR-374b-5p | NFAT5 | -0.29 | 0.00415 | -0.14 | 0.16169 | mirMAP; miRNATAP | -0.21 | 0 | NA | |
118 | hsa-miR-500a-3p | NFAT5 | 0.46 | 0.00069 | -0.14 | 0.16169 | MirTarget | -0.2 | 0 | NA | |
119 | hsa-miR-500a-5p | NFAT5 | 0.68 | 8.0E-5 | -0.14 | 0.16169 | mirMAP | -0.11 | 4.0E-5 | NA | |
120 | hsa-miR-576-5p | NFAT5 | 0.94 | 0 | -0.14 | 0.16169 | MirTarget; PITA; mirMAP | -0.1 | 0.00152 | NA | |
121 | hsa-miR-582-3p | NFAT5 | -0.25 | 0.1438 | -0.14 | 0.16169 | MirTarget | -0.1 | 0.00014 | NA | |
122 | hsa-miR-582-5p | NFAT5 | -0.04 | 0.82183 | -0.14 | 0.16169 | MirTarget; PITA; miRNATAP | -0.11 | 9.0E-5 | NA | |
123 | hsa-miR-590-5p | NFAT5 | 0.76 | 0 | -0.14 | 0.16169 | PITA; mirMAP; miRNATAP | -0.12 | 0.00036 | NA | |
124 | hsa-miR-664a-3p | NFAT5 | -0.26 | 0.05132 | -0.14 | 0.16169 | MirTarget | -0.13 | 0.00017 | NA | |
125 | hsa-miR-92a-3p | NFAT5 | 0.99 | 0 | -0.14 | 0.16169 | miRNATAP | -0.16 | 1.0E-5 | NA | |
126 | hsa-miR-93-5p | NFAT5 | 1.61 | 0 | -0.14 | 0.16169 | MirTarget; miRNATAP | -0.16 | 0 | NA | |
127 | hsa-miR-130b-5p | NFATC2 | 1.77 | 0 | -1.25 | 0.00017 | MirTarget | -0.51 | 0 | NA | |
128 | hsa-miR-16-2-3p | NFATC2 | 1.16 | 0 | -1.25 | 0.00017 | mirMAP | -0.66 | 0 | NA | |
129 | hsa-miR-182-5p | NFATC2 | 1.15 | 0 | -1.25 | 0.00017 | mirMAP | -0.55 | 0 | NA | |
130 | hsa-miR-186-5p | NFATC2 | 0.35 | 0.00015 | -1.25 | 0.00017 | mirMAP | -0.74 | 0 | NA | |
131 | hsa-miR-19a-3p | NFATC2 | 1.36 | 0 | -1.25 | 0.00017 | mirMAP | -0.92 | 0 | NA | |
132 | hsa-miR-19b-3p | NFATC2 | 0.54 | 0.00062 | -1.25 | 0.00017 | mirMAP | -1.16 | 0 | NA | |
133 | hsa-miR-205-3p | NFATC2 | 1.3 | 0 | -1.25 | 0.00017 | mirMAP | -0.34 | 0 | NA | |
134 | hsa-miR-222-3p | NFATC2 | 1.08 | 0 | -1.25 | 0.00017 | MirTarget | -0.48 | 0 | NA | |
135 | hsa-miR-2355-3p | NFATC2 | 1.58 | 0 | -1.25 | 0.00017 | mirMAP | -0.43 | 0 | NA | |
136 | hsa-miR-2355-5p | NFATC2 | 1.47 | 0 | -1.25 | 0.00017 | MirTarget | -0.59 | 0 | NA | |
137 | hsa-miR-26b-3p | NFATC2 | 0.42 | 0.00223 | -1.25 | 0.00017 | MirTarget | -0.32 | 0.00265 | NA | |
138 | hsa-miR-27b-5p | NFATC2 | 0.58 | 0.00018 | -1.25 | 0.00017 | mirMAP | -0.34 | 0.00034 | NA | |
139 | hsa-miR-29a-5p | NFATC2 | 0.32 | 0.03704 | -1.25 | 0.00017 | mirMAP; miRNATAP | -0.54 | 0 | NA | |
140 | hsa-miR-30b-5p | NFATC2 | -0.4 | 0.00347 | -1.25 | 0.00017 | MirTarget; mirMAP | -0.76 | 0 | NA | |
141 | hsa-miR-30c-5p | NFATC2 | 0.02 | 0.88637 | -1.25 | 0.00017 | MirTarget; mirMAP | -0.82 | 0 | NA | |
142 | hsa-miR-31-3p | NFATC2 | 2.1 | 0 | -1.25 | 0.00017 | MirTarget | -0.15 | 0.00014 | NA | |
143 | hsa-miR-320a | NFATC2 | 0.8 | 0 | -1.25 | 0.00017 | MirTarget | -0.6 | 0 | NA | |
144 | hsa-miR-320b | NFATC2 | 1.23 | 0 | -1.25 | 0.00017 | MirTarget | -0.3 | 0.00059 | NA | |
145 | hsa-miR-335-3p | NFATC2 | 0.34 | 0.05424 | -1.25 | 0.00017 | mirMAP | -0.29 | 0.00042 | NA | |
146 | hsa-miR-33a-3p | NFATC2 | 0.2 | 0.21234 | -1.25 | 0.00017 | mirMAP | -0.25 | 0.00723 | NA | |
147 | hsa-miR-3607-3p | NFATC2 | 1.01 | 9.0E-5 | -1.25 | 0.00017 | MirTarget; mirMAP | -0.35 | 0 | NA | |
148 | hsa-miR-3613-5p | NFATC2 | 0.41 | 0.00535 | -1.25 | 0.00017 | mirMAP | -0.61 | 0 | NA | |
149 | hsa-miR-484 | NFATC2 | 0.92 | 0 | -1.25 | 0.00017 | MirTarget | -0.48 | 6.0E-5 | NA | |
150 | hsa-miR-7-1-3p | NFATC2 | 1.14 | 0 | -1.25 | 0.00017 | mirMAP | -0.44 | 1.0E-5 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 40 | 1929 | 1.052e-30 | 4.895e-27 |
2 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 38 | 1977 | 2.052e-27 | 4.775e-24 |
3 | INTRACELLULAR SIGNAL TRANSDUCTION | 35 | 1572 | 8.999e-27 | 1.396e-23 |
4 | FC RECEPTOR SIGNALING PATHWAY | 18 | 206 | 2.513e-23 | 2.923e-20 |
5 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 14 | 74 | 3.875e-23 | 3.606e-20 |
6 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 20 | 323 | 6.382e-23 | 4.949e-20 |
7 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 26 | 876 | 5.568e-22 | 3.701e-19 |
8 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 31 | 1656 | 7.604e-21 | 4.422e-18 |
9 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 15 | 142 | 9.859e-21 | 5.097e-18 |
10 | POSITIVE REGULATION OF CELL COMMUNICATION | 30 | 1532 | 1.326e-20 | 5.61e-18 |
11 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 21 | 498 | 1.294e-20 | 5.61e-18 |
12 | REGULATION OF IMMUNE SYSTEM PROCESS | 29 | 1403 | 1.895e-20 | 7.346e-18 |
13 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 26 | 1036 | 3.751e-20 | 1.247e-17 |
14 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 26 | 1036 | 3.751e-20 | 1.247e-17 |
15 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 24 | 867 | 1.911e-19 | 5.928e-17 |
16 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 17 | 297 | 7.219e-19 | 2.099e-16 |
17 | PHOSPHOLIPID METABOLIC PROCESS | 18 | 364 | 7.673e-19 | 2.1e-16 |
18 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 29 | 1618 | 9.513e-19 | 2.459e-16 |
19 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 15 | 193 | 1.108e-18 | 2.713e-16 |
20 | PHOSPHATIDYLETHANOLAMINE ACYL CHAIN REMODELING | 9 | 23 | 2.078e-18 | 4.833e-16 |
21 | POSITIVE REGULATION OF MAPK CASCADE | 19 | 470 | 2.925e-18 | 6.481e-16 |
22 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 15 | 211 | 4.293e-18 | 9.08e-16 |
23 | POSITIVE REGULATION OF KINASE ACTIVITY | 19 | 482 | 4.676e-18 | 9.459e-16 |
24 | REGULATION OF KINASE ACTIVITY | 22 | 776 | 6.056e-18 | 1.174e-15 |
25 | PHOSPHATIDYLCHOLINE ACYL CHAIN REMODELING | 9 | 26 | 7.898e-18 | 1.47e-15 |
26 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 21 | 689 | 9.967e-18 | 1.784e-15 |
27 | ACTIVATION OF IMMUNE RESPONSE | 18 | 427 | 1.305e-17 | 2.25e-15 |
28 | GLYCEROLIPID METABOLIC PROCESS | 17 | 356 | 1.54e-17 | 2.559e-15 |
29 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 15 | 235 | 2.185e-17 | 3.505e-15 |
30 | REGULATION OF IMMUNE RESPONSE | 22 | 858 | 5.028e-17 | 7.799e-15 |
31 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 24 | 1135 | 9.074e-17 | 1.362e-14 |
32 | CELLULAR LIPID METABOLIC PROCESS | 22 | 913 | 1.847e-16 | 2.686e-14 |
33 | IMMUNE SYSTEM PROCESS | 29 | 1984 | 2.365e-16 | 3.335e-14 |
34 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 26 | 1492 | 2.962e-16 | 4.053e-14 |
35 | REGULATION OF TRANSFERASE ACTIVITY | 22 | 946 | 3.874e-16 | 5.15e-14 |
36 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 19 | 616 | 4.313e-16 | 5.574e-14 |
37 | PHOSPHORYLATION | 24 | 1228 | 5.362e-16 | 6.744e-14 |
38 | FC GAMMA RECEPTOR SIGNALING PATHWAY | 11 | 95 | 7.869e-16 | 9.635e-14 |
39 | LOCOMOTION | 23 | 1114 | 8.55e-16 | 1.02e-13 |
40 | REGULATION OF MAPK CASCADE | 19 | 660 | 1.519e-15 | 1.723e-13 |
41 | VASCULATURE DEVELOPMENT | 17 | 469 | 1.518e-15 | 1.723e-13 |
42 | PLATELET ACTIVATION | 12 | 142 | 1.656e-15 | 1.792e-13 |
43 | POSITIVE REGULATION OF IMMUNE RESPONSE | 18 | 563 | 1.654e-15 | 1.792e-13 |
44 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 27 | 1791 | 2.195e-15 | 2.321e-13 |
45 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 13 | 207 | 4.768e-15 | 4.93e-13 |
46 | PROTEIN PHOSPHORYLATION | 21 | 944 | 5.452e-15 | 5.515e-13 |
47 | PHOSPHATIDYLINOSITOL ACYL CHAIN REMODELING | 7 | 16 | 5.927e-15 | 5.867e-13 |
48 | PHOSPHATIDYLGLYCEROL METABOLIC PROCESS | 8 | 31 | 8.951e-15 | 8.677e-13 |
49 | PHOSPHATIDYLSERINE ACYL CHAIN REMODELING | 7 | 17 | 1.006e-14 | 9.357e-13 |
50 | PHOSPHATIDYLGLYCEROL ACYL CHAIN REMODELING | 7 | 17 | 1.006e-14 | 9.357e-13 |
51 | LIPID BIOSYNTHETIC PROCESS | 17 | 539 | 1.491e-14 | 1.361e-12 |
52 | LIPID METABOLIC PROCESS | 22 | 1158 | 2.518e-14 | 2.253e-12 |
53 | REGULATION OF TRANSPORT | 26 | 1804 | 2.808e-14 | 2.466e-12 |
54 | REGULATION OF RESPONSE TO STRESS | 24 | 1468 | 2.863e-14 | 2.467e-12 |
55 | CELL ACTIVATION | 17 | 568 | 3.507e-14 | 2.967e-12 |
56 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 19 | 788 | 3.738e-14 | 3.051e-12 |
57 | CIRCULATORY SYSTEM DEVELOPMENT | 19 | 788 | 3.738e-14 | 3.051e-12 |
58 | REGULATION OF MAP KINASE ACTIVITY | 14 | 319 | 5.321e-14 | 4.269e-12 |
59 | PHOSPHATIDYLCHOLINE METABOLIC PROCESS | 9 | 64 | 6.466e-14 | 5.1e-12 |
60 | REGULATION OF PROTEIN MODIFICATION PROCESS | 25 | 1710 | 8.269e-14 | 6.412e-12 |
61 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 20 | 957 | 9.571e-14 | 7.3e-12 |
62 | POSITIVE REGULATION OF LOCOMOTION | 15 | 420 | 1.172e-13 | 8.799e-12 |
63 | ORGANOPHOSPHATE METABOLIC PROCESS | 19 | 885 | 2.968e-13 | 2.192e-11 |
64 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 15 | 450 | 3.184e-13 | 2.315e-11 |
65 | RESPONSE TO EXTERNAL STIMULUS | 25 | 1821 | 3.442e-13 | 2.464e-11 |
66 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 13 | 289 | 3.51e-13 | 2.475e-11 |
67 | ANGIOGENESIS | 13 | 293 | 4.182e-13 | 2.904e-11 |
68 | ERBB SIGNALING PATHWAY | 9 | 79 | 4.694e-13 | 3.212e-11 |
69 | TAXIS | 15 | 464 | 4.953e-13 | 3.34e-11 |
70 | PHOSPHATIDYLSERINE METABOLIC PROCESS | 7 | 28 | 5.991e-13 | 3.982e-11 |
71 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 23 | 1518 | 6.165e-13 | 4.04e-11 |
72 | HEMOSTASIS | 13 | 311 | 8.924e-13 | 5.767e-11 |
73 | ETHANOLAMINE CONTAINING COMPOUND METABOLIC PROCESS | 9 | 85 | 9.281e-13 | 5.916e-11 |
74 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 22 | 1395 | 1.092e-12 | 6.866e-11 |
75 | LIPID CATABOLIC PROCESS | 12 | 247 | 1.284e-12 | 7.969e-11 |
76 | EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 8 | 55 | 1.318e-12 | 8.069e-11 |
77 | REGULATION OF BODY FLUID LEVELS | 15 | 506 | 1.719e-12 | 1.039e-10 |
78 | PHAGOCYTOSIS | 11 | 190 | 1.83e-12 | 1.092e-10 |
79 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 21 | 1275 | 1.903e-12 | 1.121e-10 |
80 | LEUKOCYTE MIGRATION | 12 | 259 | 2.248e-12 | 1.307e-10 |
81 | ALDITOL PHOSPHATE METABOLIC PROCESS | 7 | 35 | 3.356e-12 | 1.928e-10 |
82 | BLOOD VESSEL MORPHOGENESIS | 13 | 364 | 6.501e-12 | 3.689e-10 |
83 | WOUND HEALING | 14 | 470 | 1.011e-11 | 5.602e-10 |
84 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 14 | 470 | 1.011e-11 | 5.602e-10 |
85 | IMMUNE EFFECTOR PROCESS | 14 | 486 | 1.58e-11 | 8.649e-10 |
86 | AMMONIUM ION METABOLIC PROCESS | 10 | 169 | 1.654e-11 | 8.893e-10 |
87 | CELL MOTILITY | 17 | 835 | 1.682e-11 | 8.893e-10 |
88 | LOCALIZATION OF CELL | 17 | 835 | 1.682e-11 | 8.893e-10 |
89 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 23 | 1805 | 2.207e-11 | 1.154e-09 |
90 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 13 | 404 | 2.394e-11 | 1.238e-09 |
91 | ENDOCYTOSIS | 14 | 509 | 2.921e-11 | 1.493e-09 |
92 | AMINE METABOLIC PROCESS | 9 | 131 | 4.874e-11 | 2.465e-09 |
93 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 10 | 195 | 6.828e-11 | 3.416e-09 |
94 | ALCOHOL METABOLIC PROCESS | 12 | 348 | 7.047e-11 | 3.488e-09 |
95 | CALCIUM MEDIATED SIGNALING | 8 | 90 | 7.834e-11 | 3.827e-09 |
96 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 20 | 1381 | 7.895e-11 | 3.827e-09 |
97 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 16 | 799 | 9.778e-11 | 4.69e-09 |
98 | RESPONSE TO WOUNDING | 14 | 563 | 1.106e-10 | 5.249e-09 |
99 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 11 | 279 | 1.164e-10 | 5.47e-09 |
100 | PEPTIDYL SERINE MODIFICATION | 9 | 148 | 1.461e-10 | 6.799e-09 |
101 | IMMUNE SYSTEM DEVELOPMENT | 14 | 582 | 1.709e-10 | 7.874e-09 |
102 | POSITIVE REGULATION OF HOMEOSTATIC PROCESS | 10 | 216 | 1.866e-10 | 8.514e-09 |
103 | POSITIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 11 | 296 | 2.185e-10 | 9.871e-09 |
104 | PHOSPHATIDIC ACID METABOLIC PROCESS | 6 | 33 | 2.407e-10 | 1.077e-08 |
105 | REGULATION OF CELL DEATH | 20 | 1472 | 2.461e-10 | 1.08e-08 |
106 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 18 | 1142 | 2.44e-10 | 1.08e-08 |
107 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 18 | 1152 | 2.81e-10 | 1.222e-08 |
108 | SECOND MESSENGER MEDIATED SIGNALING | 9 | 160 | 2.934e-10 | 1.264e-08 |
109 | REGULATION OF CELL DIFFERENTIATION | 20 | 1492 | 3.125e-10 | 1.334e-08 |
110 | REGULATION OF CELL PROLIFERATION | 20 | 1496 | 3.277e-10 | 1.386e-08 |
111 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 17 | 1021 | 3.842e-10 | 1.611e-08 |
112 | REGULATION OF INTRACELLULAR TRANSPORT | 14 | 621 | 3.987e-10 | 1.657e-08 |
113 | REGULATION OF CELL ADHESION | 14 | 629 | 4.71e-10 | 1.939e-08 |
114 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 15 | 771 | 6.389e-10 | 2.608e-08 |
115 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 8 | 120 | 8.007e-10 | 3.24e-08 |
116 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 6 | 40 | 8.227e-10 | 3.3e-08 |
117 | VESICLE MEDIATED TRANSPORT | 18 | 1239 | 9.074e-10 | 3.609e-08 |
118 | POSITIVE REGULATION OF TRANSPORT | 16 | 936 | 9.885e-10 | 3.898e-08 |
119 | REGULATION OF HOMEOSTATIC PROCESS | 12 | 447 | 1.232e-09 | 4.819e-08 |
120 | POSITIVE REGULATION OF CELL PROLIFERATION | 15 | 814 | 1.345e-09 | 5.215e-08 |
121 | SINGLE ORGANISM CATABOLIC PROCESS | 16 | 957 | 1.362e-09 | 5.239e-08 |
122 | CELLULAR RESPONSE TO GROWTH HORMONE STIMULUS | 5 | 20 | 1.468e-09 | 5.563e-08 |
123 | REGULATION OF CELLULAR LOCALIZATION | 18 | 1277 | 1.471e-09 | 5.563e-08 |
124 | POSITIVE REGULATION OF VASCULATURE DEVELOPMENT | 8 | 133 | 1.82e-09 | 6.829e-08 |
125 | POSITIVE REGULATION OF DEFENSE RESPONSE | 11 | 364 | 1.935e-09 | 7.202e-08 |
126 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 20 | 1672 | 2.302e-09 | 8.439e-08 |
127 | ACTIVATION OF MAPK ACTIVITY | 8 | 137 | 2.303e-09 | 8.439e-08 |
128 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 8 | 138 | 2.44e-09 | 8.871e-08 |
129 | REGULATION OF LIPID METABOLIC PROCESS | 10 | 282 | 2.486e-09 | 8.968e-08 |
130 | REGULATION OF LIPID KINASE ACTIVITY | 6 | 48 | 2.589e-09 | 9.266e-08 |
131 | RESPONSE TO NITROGEN COMPOUND | 15 | 859 | 2.8e-09 | 9.928e-08 |
132 | REGULATION OF CYTOPLASMIC TRANSPORT | 12 | 481 | 2.816e-09 | 9.928e-08 |
133 | ORGANIC HYDROXY COMPOUND METABOLIC PROCESS | 12 | 482 | 2.883e-09 | 1.009e-07 |
134 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 6 | 49 | 2.944e-09 | 1.022e-07 |
135 | T CELL RECEPTOR SIGNALING PATHWAY | 8 | 146 | 3.815e-09 | 1.315e-07 |
136 | POSITIVE REGULATION OF GENE EXPRESSION | 20 | 1733 | 4.281e-09 | 1.465e-07 |
137 | POSITIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 5 | 25 | 4.981e-09 | 1.68e-07 |
138 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 25 | 4.981e-09 | 1.68e-07 |
139 | LIPID PHOSPHORYLATION | 7 | 99 | 6.548e-09 | 2.192e-07 |
140 | REGULATION OF RESPONSE TO WOUNDING | 11 | 413 | 7.2e-09 | 2.393e-07 |
141 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 15 | 926 | 7.725e-09 | 2.549e-07 |
142 | RESPONSE TO ENDOGENOUS STIMULUS | 18 | 1450 | 1.092e-08 | 3.58e-07 |
143 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 6 | 61 | 1.142e-08 | 3.715e-07 |
144 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 20 | 1848 | 1.288e-08 | 4.163e-07 |
145 | RESPONSE TO GROWTH HORMONE | 5 | 30 | 1.323e-08 | 4.246e-07 |
146 | REGULATION OF CELL SUBSTRATE ADHESION | 8 | 173 | 1.45e-08 | 4.621e-07 |
147 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 14 | 823 | 1.475e-08 | 4.668e-07 |
148 | REGULATION OF ENDOTHELIAL CELL MIGRATION | 7 | 114 | 1.757e-08 | 5.524e-07 |
149 | REGULATION OF GOLGI ORGANIZATION | 4 | 12 | 1.98e-08 | 6.142e-07 |
150 | TRACHEA MORPHOGENESIS | 4 | 12 | 1.98e-08 | 6.142e-07 |
151 | POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 6 | 67 | 2.028e-08 | 6.249e-07 |
152 | REGULATION OF VESICLE MEDIATED TRANSPORT | 11 | 462 | 2.283e-08 | 6.99e-07 |
153 | SINGLE ORGANISM BIOSYNTHETIC PROCESS | 17 | 1340 | 2.317e-08 | 7.045e-07 |
154 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 10 | 360 | 2.547e-08 | 7.696e-07 |
155 | RESPONSE TO ABIOTIC STIMULUS | 15 | 1024 | 2.959e-08 | 8.883e-07 |
156 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 10 | 370 | 3.297e-08 | 9.834e-07 |
157 | REGULATION OF CELL ACTIVATION | 11 | 484 | 3.672e-08 | 1.088e-06 |
158 | RESPONSE TO BIOTIC STIMULUS | 14 | 886 | 3.719e-08 | 1.095e-06 |
159 | SMALL MOLECULE METABOLIC PROCESS | 19 | 1767 | 3.828e-08 | 1.12e-06 |
160 | REGULATION OF CELL CELL ADHESION | 10 | 380 | 4.236e-08 | 1.232e-06 |
161 | REGULATION OF DEFENSE RESPONSE | 13 | 759 | 4.939e-08 | 1.427e-06 |
162 | ERBB2 SIGNALING PATHWAY | 5 | 39 | 5.252e-08 | 1.509e-06 |
163 | NEURON PROJECTION GUIDANCE | 8 | 205 | 5.433e-08 | 1.551e-06 |
164 | LIPID MODIFICATION | 8 | 210 | 6.545e-08 | 1.857e-06 |
165 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 11 | 514 | 6.765e-08 | 1.908e-06 |
166 | REGULATION OF EARLY ENDOSOME TO LATE ENDOSOME TRANSPORT | 4 | 16 | 7.224e-08 | 2.025e-06 |
167 | MODULATION OF SYNAPTIC TRANSMISSION | 9 | 301 | 7.333e-08 | 2.043e-06 |
168 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 9 | 307 | 8.677e-08 | 2.403e-06 |
169 | RESPONSE TO BACTERIUM | 11 | 528 | 8.877e-08 | 2.444e-06 |
170 | LUNG MORPHOGENESIS | 5 | 45 | 1.101e-07 | 3.015e-06 |
171 | REGULATION OF CELL MATRIX ADHESION | 6 | 90 | 1.209e-07 | 3.273e-06 |
172 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 4 | 18 | 1.21e-07 | 3.273e-06 |
173 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 9 | 321 | 1.268e-07 | 3.41e-06 |
174 | REGULATION OF SYNAPSE STRUCTURE OR ACTIVITY | 8 | 232 | 1.409e-07 | 3.768e-06 |
175 | REGULATION OF VASCULATURE DEVELOPMENT | 8 | 233 | 1.456e-07 | 3.872e-06 |
176 | HOMEOSTATIC PROCESS | 16 | 1337 | 1.514e-07 | 4.001e-06 |
177 | REGULATION OF CELL PROJECTION ORGANIZATION | 11 | 558 | 1.548e-07 | 4.069e-06 |
178 | ICOSANOID METABOLIC PROCESS | 6 | 96 | 1.779e-07 | 4.624e-06 |
179 | FATTY ACID DERIVATIVE METABOLIC PROCESS | 6 | 96 | 1.779e-07 | 4.624e-06 |
180 | REGULATION OF ORGANELLE ORGANIZATION | 15 | 1178 | 1.855e-07 | 4.795e-06 |
181 | TRACHEA DEVELOPMENT | 4 | 20 | 1.908e-07 | 4.906e-06 |
182 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 5 | 51 | 2.093e-07 | 5.322e-06 |
183 | REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 5 | 51 | 2.093e-07 | 5.322e-06 |
184 | CELLULAR RESPONSE TO STRESS | 17 | 1565 | 2.214e-07 | 5.6e-06 |
185 | REGULATION OF EPITHELIAL CELL MIGRATION | 7 | 166 | 2.336e-07 | 5.875e-06 |
186 | NEGATIVE REGULATION OF CELL DEATH | 13 | 872 | 2.463e-07 | 6.16e-06 |
187 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 6 | 103 | 2.706e-07 | 6.733e-06 |
188 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 9 | 352 | 2.764e-07 | 6.84e-06 |
189 | B CELL RECEPTOR SIGNALING PATHWAY | 5 | 54 | 2.801e-07 | 6.897e-06 |
190 | POSITIVE REGULATION OF PROTEIN IMPORT | 6 | 104 | 2.866e-07 | 6.993e-06 |
191 | ERK1 AND ERK2 CASCADE | 4 | 22 | 2.87e-07 | 6.993e-06 |
192 | POSITIVE REGULATION OF ERK1 AND ERK2 CASCADE | 7 | 172 | 2.973e-07 | 7.206e-06 |
193 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 8 | 258 | 3.17e-07 | 7.644e-06 |
194 | RESPONSE TO HORMONE | 13 | 893 | 3.233e-07 | 7.754e-06 |
195 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 8 | 263 | 3.668e-07 | 8.753e-06 |
196 | ENDOTHELIAL CELL MIGRATION | 5 | 57 | 3.687e-07 | 8.753e-06 |
197 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 9 | 365 | 3.748e-07 | 8.852e-06 |
198 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 9 | 368 | 4.014e-07 | 9.433e-06 |
199 | THYROID GLAND DEVELOPMENT | 4 | 25 | 4.935e-07 | 1.154e-05 |
200 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 10 | 505 | 5.887e-07 | 1.37e-05 |
201 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 8 | 282 | 6.219e-07 | 1.44e-05 |
202 | REGULATION OF PROTEIN LOCALIZATION | 13 | 950 | 6.528e-07 | 1.504e-05 |
203 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 10 | 513 | 6.792e-07 | 1.557e-05 |
204 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 121 | 7.02e-07 | 1.601e-05 |
205 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 7 | 197 | 7.434e-07 | 1.679e-05 |
206 | RESPIRATORY SYSTEM DEVELOPMENT | 7 | 197 | 7.434e-07 | 1.679e-05 |
207 | LEUKOCYTE DIFFERENTIATION | 8 | 292 | 8.086e-07 | 1.814e-05 |
208 | INOSITOL LIPID MEDIATED SIGNALING | 6 | 124 | 8.108e-07 | 1.814e-05 |
209 | NEURON PROJECTION MORPHOGENESIS | 9 | 402 | 8.39e-07 | 1.868e-05 |
210 | REGULATION OF VACUOLAR TRANSPORT | 4 | 29 | 9.195e-07 | 2.037e-05 |
211 | POSITIVE REGULATION OF LIPID METABOLIC PROCESS | 6 | 128 | 9.77e-07 | 2.155e-05 |
212 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 129 | 1.023e-06 | 2.245e-05 |
213 | PHOSPHOLIPID CATABOLIC PROCESS | 4 | 30 | 1.059e-06 | 2.313e-05 |
214 | LEUKOCYTE ACTIVATION | 9 | 414 | 1.071e-06 | 2.317e-05 |
215 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 8 | 303 | 1.067e-06 | 2.317e-05 |
216 | CELL DEATH | 13 | 1001 | 1.176e-06 | 2.533e-05 |
217 | LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 4 | 31 | 1.214e-06 | 2.602e-05 |
218 | PEPTIDYL AMINO ACID MODIFICATION | 12 | 841 | 1.235e-06 | 2.636e-05 |
219 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 10 | 552 | 1.319e-06 | 2.801e-05 |
220 | PLACENTA DEVELOPMENT | 6 | 138 | 1.518e-06 | 3.21e-05 |
221 | CELLULAR MODIFIED AMINO ACID METABOLIC PROCESS | 7 | 220 | 1.556e-06 | 3.277e-05 |
222 | REGULATION OF CYTOKINE PRODUCTION | 10 | 563 | 1.575e-06 | 3.301e-05 |
223 | REGULATION OF SYNAPTIC PLASTICITY | 6 | 140 | 1.651e-06 | 3.444e-05 |
224 | NEUROGENESIS | 15 | 1402 | 1.701e-06 | 3.534e-05 |
225 | ORGAN FORMATION | 4 | 34 | 1.778e-06 | 3.678e-05 |
226 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 10 | 573 | 1.844e-06 | 3.797e-05 |
227 | RAS PROTEIN SIGNAL TRANSDUCTION | 6 | 143 | 1.868e-06 | 3.828e-05 |
228 | CELL DEVELOPMENT | 15 | 1426 | 2.103e-06 | 4.291e-05 |
229 | RESPONSE TO LIPID | 12 | 888 | 2.178e-06 | 4.426e-05 |
230 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 8 | 337 | 2.36e-06 | 4.774e-05 |
231 | SINGLE ORGANISM CELL ADHESION | 9 | 459 | 2.503e-06 | 5.021e-05 |
232 | CELLULAR COMPONENT MORPHOGENESIS | 12 | 900 | 2.503e-06 | 5.021e-05 |
233 | CELL PROJECTION ORGANIZATION | 12 | 902 | 2.562e-06 | 5.116e-05 |
234 | TISSUE MIGRATION | 5 | 84 | 2.579e-06 | 5.127e-05 |
235 | LYMPHOCYTE ACTIVATION | 8 | 342 | 2.632e-06 | 5.19e-05 |
236 | REGULATION OF ERK1 AND ERK2 CASCADE | 7 | 238 | 2.624e-06 | 5.19e-05 |
237 | HEART DEVELOPMENT | 9 | 466 | 2.833e-06 | 5.561e-05 |
238 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 6 | 154 | 2.873e-06 | 5.617e-05 |
239 | POSITIVE REGULATION OF DNA REPLICATION | 5 | 86 | 2.897e-06 | 5.641e-05 |
240 | ASTROCYTE DIFFERENTIATION | 4 | 39 | 3.124e-06 | 6.056e-05 |
241 | RESPONSE TO GROWTH FACTOR | 9 | 475 | 3.311e-06 | 6.392e-05 |
242 | EPITHELIAL CELL PROLIFERATION | 5 | 89 | 3.433e-06 | 6.601e-05 |
243 | POSITIVE REGULATION OF RESPONSE TO WOUNDING | 6 | 162 | 3.851e-06 | 7.374e-05 |
244 | REGULATION OF PEPTIDE TRANSPORT | 7 | 256 | 4.245e-06 | 8.096e-05 |
245 | CELL PART MORPHOGENESIS | 10 | 633 | 4.477e-06 | 8.502e-05 |
246 | TISSUE DEVELOPMENT | 15 | 1518 | 4.555e-06 | 8.615e-05 |
247 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 8 | 370 | 4.704e-06 | 8.862e-05 |
248 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 5 | 95 | 4.736e-06 | 8.875e-05 |
249 | RESPONSE TO CARBOHYDRATE | 6 | 168 | 4.749e-06 | 8.875e-05 |
250 | POSITIVE REGULATION OF CELL ADHESION | 8 | 376 | 5.294e-06 | 9.853e-05 |
251 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 8 | 381 | 5.832e-06 | 0.0001081 |
252 | ICOSANOID BIOSYNTHETIC PROCESS | 4 | 46 | 6.115e-06 | 0.0001125 |
253 | FATTY ACID DERIVATIVE BIOSYNTHETIC PROCESS | 4 | 46 | 6.115e-06 | 0.0001125 |
254 | CATABOLIC PROCESS | 16 | 1773 | 6.435e-06 | 0.0001179 |
255 | CELLULAR RESPONSE TO PEPTIDE | 7 | 274 | 6.628e-06 | 0.0001209 |
256 | THYMUS DEVELOPMENT | 4 | 47 | 6.671e-06 | 0.0001213 |
257 | CELL PROLIFERATION | 10 | 672 | 7.576e-06 | 0.0001372 |
258 | REGULATION OF PROTEIN IMPORT | 6 | 183 | 7.76e-06 | 0.00014 |
259 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 12 | 1008 | 7.999e-06 | 0.0001437 |
260 | REGULATION OF ADHERENS JUNCTION ORGANIZATION | 4 | 50 | 8.564e-06 | 0.0001515 |
261 | ORGAN MORPHOGENESIS | 11 | 841 | 8.467e-06 | 0.0001515 |
262 | FACE DEVELOPMENT | 4 | 50 | 8.564e-06 | 0.0001515 |
263 | ARACHIDONIC ACID METABOLIC PROCESS | 4 | 50 | 8.564e-06 | 0.0001515 |
264 | RESPONSE TO PEPTIDE | 8 | 404 | 8.945e-06 | 0.0001577 |
265 | UNSATURATED FATTY ACID METABOLIC PROCESS | 5 | 109 | 9.292e-06 | 0.0001632 |
266 | REPRODUCTIVE SYSTEM DEVELOPMENT | 8 | 408 | 9.61e-06 | 0.0001681 |
267 | REGULATION OF CELLULAR RESPONSE TO STRESS | 10 | 691 | 9.666e-06 | 0.0001685 |
268 | NEURON PROJECTION DEVELOPMENT | 9 | 545 | 1.004e-05 | 0.0001744 |
269 | PROTEIN AUTOPHOSPHORYLATION | 6 | 192 | 1.021e-05 | 0.0001766 |
270 | FATTY ACID METABOLIC PROCESS | 7 | 296 | 1.096e-05 | 0.0001889 |
271 | REGULATION OF MUSCLE SYSTEM PROCESS | 6 | 195 | 1.115e-05 | 0.0001901 |
272 | POSITIVE REGULATION OF INFLAMMATORY RESPONSE | 5 | 113 | 1.108e-05 | 0.0001901 |
273 | REGULATION OF CELL MORPHOGENESIS | 9 | 552 | 1.112e-05 | 0.0001901 |
274 | CHEMICAL HOMEOSTASIS | 11 | 874 | 1.216e-05 | 0.0002058 |
275 | NEURON DIFFERENTIATION | 11 | 874 | 1.216e-05 | 0.0002058 |
276 | RESPONSE TO CYTOKINE | 10 | 714 | 1.285e-05 | 0.0002166 |
277 | OVULATION | 3 | 18 | 1.316e-05 | 0.0002203 |
278 | MAST CELL MEDIATED IMMUNITY | 3 | 18 | 1.316e-05 | 0.0002203 |
279 | REGULATION OF PROTEIN TARGETING | 7 | 307 | 1.388e-05 | 0.0002315 |
280 | CYTOKINE PRODUCTION | 5 | 120 | 1.483e-05 | 0.0002465 |
281 | REGULATION OF CALCIUM ION TRANSPORT | 6 | 209 | 1.653e-05 | 0.0002737 |
282 | POSITIVE REGULATION OF CYCLASE ACTIVITY | 4 | 61 | 1.9e-05 | 0.0003135 |
283 | INFLAMMATORY RESPONSE | 8 | 454 | 2.077e-05 | 0.0003415 |
284 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 218 | 2.098e-05 | 0.0003437 |
285 | MAST CELL ACTIVATION | 3 | 21 | 2.133e-05 | 0.000347 |
286 | POSITIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION | 3 | 21 | 2.133e-05 | 0.000347 |
287 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 220 | 2.208e-05 | 0.0003574 |
288 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 9 | 602 | 2.212e-05 | 0.0003574 |
289 | RESPONSE TO METAL ION | 7 | 333 | 2.342e-05 | 0.000377 |
290 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 10 | 767 | 2.382e-05 | 0.0003821 |
291 | CELLULAR RESPONSE TO VIRUS | 3 | 22 | 2.465e-05 | 0.0003942 |
292 | CELLULAR RESPONSE TO UV | 4 | 66 | 2.599e-05 | 0.0004142 |
293 | CELLULAR RESPONSE TO RADIATION | 5 | 137 | 2.813e-05 | 0.0004467 |
294 | LYSOSOME LOCALIZATION | 3 | 23 | 2.83e-05 | 0.0004479 |
295 | REGULATION OF CELL JUNCTION ASSEMBLY | 4 | 68 | 2.926e-05 | 0.0004615 |
296 | RESPONSE TO INORGANIC SUBSTANCE | 8 | 479 | 3.046e-05 | 0.0004788 |
297 | POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY | 3 | 24 | 3.228e-05 | 0.0005058 |
298 | MUSCLE CELL DIFFERENTIATION | 6 | 237 | 3.354e-05 | 0.0005238 |
299 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 4 | 71 | 3.471e-05 | 0.0005401 |
300 | RESPONSE TO TOXIC SUBSTANCE | 6 | 241 | 3.684e-05 | 0.0005713 |
301 | POSITIVE REGULATION OF AUTOPHAGY | 4 | 75 | 4.308e-05 | 0.000666 |
302 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 11 | 1004 | 4.382e-05 | 0.0006751 |
303 | CELLULAR LIPID CATABOLIC PROCESS | 5 | 151 | 4.482e-05 | 0.0006883 |
304 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 5 | 152 | 4.626e-05 | 0.0007078 |
305 | RESPONSE TO LITHIUM ION | 3 | 27 | 4.64e-05 | 0.0007078 |
306 | REGULATION OF NEURON DEATH | 6 | 252 | 4.724e-05 | 0.0007184 |
307 | AMEBOIDAL TYPE CELL MIGRATION | 5 | 154 | 4.923e-05 | 0.0007462 |
308 | REGULATION OF CELL DEVELOPMENT | 10 | 836 | 4.949e-05 | 0.0007477 |
309 | LYMPHOCYTE COSTIMULATION | 4 | 78 | 5.027e-05 | 0.0007545 |
310 | REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 4 | 78 | 5.027e-05 | 0.0007545 |
311 | LEUKOCYTE CELL CELL ADHESION | 6 | 255 | 5.046e-05 | 0.0007549 |
312 | POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE | 3 | 28 | 5.187e-05 | 0.0007736 |
313 | CELLULAR HOMEOSTASIS | 9 | 676 | 5.466e-05 | 0.0008126 |
314 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 4 | 80 | 5.553e-05 | 0.0008228 |
315 | BIOLOGICAL ADHESION | 11 | 1032 | 5.624e-05 | 0.0008308 |
316 | POSITIVE REGULATION OF INSULIN SECRETION INVOLVED IN CELLULAR RESPONSE TO GLUCOSE STIMULUS | 3 | 29 | 5.775e-05 | 0.0008503 |
317 | DEFENSE RESPONSE | 12 | 1231 | 5.806e-05 | 0.0008523 |
318 | REGULATION OF DNA REPLICATION | 5 | 161 | 6.082e-05 | 0.00089 |
319 | NEURON DEVELOPMENT | 9 | 687 | 6.191e-05 | 0.000903 |
320 | REGULATION OF PROTEIN SECRETION | 7 | 389 | 6.28e-05 | 0.0009103 |
321 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 5 | 162 | 6.264e-05 | 0.0009103 |
322 | LEUKOCYTE DEGRANULATION | 3 | 30 | 6.405e-05 | 0.0009198 |
323 | RESPONSE TO EPIDERMAL GROWTH FACTOR | 3 | 30 | 6.405e-05 | 0.0009198 |
324 | CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS | 3 | 30 | 6.405e-05 | 0.0009198 |
325 | POSITIVE REGULATION OF MUSCLE CELL DIFFERENTIATION | 4 | 84 | 6.722e-05 | 0.0009624 |
326 | GLAND DEVELOPMENT | 7 | 395 | 6.914e-05 | 0.0009868 |
327 | EPHRIN RECEPTOR SIGNALING PATHWAY | 4 | 85 | 7.041e-05 | 0.001002 |
328 | REGULATION OF SECRETION | 9 | 699 | 7.072e-05 | 0.001003 |
329 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 6 | 272 | 7.213e-05 | 0.00102 |
330 | POSITIVE REGULATION OF LIPID KINASE ACTIVITY | 3 | 32 | 7.796e-05 | 0.001099 |
331 | HEAD DEVELOPMENT | 9 | 709 | 7.886e-05 | 0.001109 |
332 | LONG CHAIN FATTY ACID METABOLIC PROCESS | 4 | 88 | 8.062e-05 | 0.00113 |
333 | TISSUE HOMEOSTASIS | 5 | 171 | 8.092e-05 | 0.001131 |
334 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 7 | 406 | 8.211e-05 | 0.001144 |
335 | CELLULAR RESPONSE TO HORMONE STIMULUS | 8 | 552 | 8.266e-05 | 0.001145 |
336 | TUBE DEVELOPMENT | 8 | 552 | 8.266e-05 | 0.001145 |
337 | REGULATION OF NEURON DIFFERENTIATION | 8 | 554 | 8.477e-05 | 0.001167 |
338 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 7 | 408 | 8.467e-05 | 0.001167 |
339 | STRIATED MUSCLE CELL DIFFERENTIATION | 5 | 173 | 8.549e-05 | 0.001171 |
340 | CELLULAR SENESCENCE | 3 | 33 | 8.56e-05 | 0.001171 |
341 | EMBRYO DEVELOPMENT | 10 | 894 | 8.672e-05 | 0.001183 |
342 | SINGLE ORGANISM CELLULAR LOCALIZATION | 10 | 898 | 8.999e-05 | 0.001224 |
343 | CELLULAR RESPONSE TO LIGHT STIMULUS | 4 | 91 | 9.187e-05 | 0.001246 |
344 | RESPONSE TO CORTICOSTEROID | 5 | 176 | 9.271e-05 | 0.001254 |
345 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 6 | 285 | 9.327e-05 | 0.001258 |
346 | REPRODUCTION | 12 | 1297 | 9.594e-05 | 0.00129 |
347 | APOPTOTIC SIGNALING PATHWAY | 6 | 289 | 0.0001007 | 0.00135 |
348 | CELLULAR CHEMICAL HOMEOSTASIS | 8 | 570 | 0.0001033 | 0.001381 |
349 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 10 | 917 | 0.000107 | 0.001427 |
350 | REGULATION OF INFLAMMATORY RESPONSE | 6 | 294 | 0.0001106 | 0.00147 |
351 | MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 96 | 0.0001131 | 0.001499 |
352 | POSITIVE REGULATION OF DNA METABOLIC PROCESS | 5 | 185 | 0.0001172 | 0.001549 |
353 | PEPTIDYL TYROSINE MODIFICATION | 5 | 186 | 0.0001202 | 0.001585 |
354 | MYELOID LEUKOCYTE MIGRATION | 4 | 99 | 0.0001274 | 0.00167 |
355 | POSITIVE REGULATION OF CELL SUBSTRATE ADHESION | 4 | 99 | 0.0001274 | 0.00167 |
356 | MYELOID CELL DIFFERENTIATION | 5 | 189 | 0.0001296 | 0.001694 |
357 | REGULATION OF GLUCOSE TRANSPORT | 4 | 100 | 0.0001325 | 0.001727 |
358 | RESPONSE TO REACTIVE OXYGEN SPECIES | 5 | 191 | 0.0001361 | 0.001769 |
359 | REGULATION OF NEURON APOPTOTIC PROCESS | 5 | 192 | 0.0001395 | 0.001808 |
360 | ORGANONITROGEN COMPOUND METABOLIC PROCESS | 14 | 1796 | 0.0001416 | 0.001823 |
361 | PEPTIDYL TYROSINE AUTOPHOSPHORYLATION | 3 | 39 | 0.0001418 | 0.001823 |
362 | POSITIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 3 | 39 | 0.0001418 | 0.001823 |
363 | POSITIVE REGULATION OF CELL ACTIVATION | 6 | 311 | 0.0001503 | 0.001926 |
364 | POSITIVE REGULATION OF CELL MATRIX ADHESION | 3 | 40 | 0.000153 | 0.001956 |
365 | POSITIVE REGULATION OF CELL DEATH | 8 | 605 | 0.0001557 | 0.001985 |
366 | CELL CELL ADHESION | 8 | 608 | 0.000161 | 0.002047 |
367 | MYELOID CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 3 | 41 | 0.0001648 | 0.002089 |
368 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 4 | 106 | 0.0001659 | 0.002098 |
369 | POSITIVE REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 3 | 42 | 0.0001772 | 0.002228 |
370 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 3 | 42 | 0.0001772 | 0.002228 |
371 | ACTIVATION OF INNATE IMMUNE RESPONSE | 5 | 204 | 0.0001851 | 0.002321 |
372 | REGULATION OF SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 3 | 43 | 0.0001901 | 0.002371 |
373 | MYELOID LEUKOCYTE MEDIATED IMMUNITY | 3 | 43 | 0.0001901 | 0.002371 |
374 | REGULATION OF METAL ION TRANSPORT | 6 | 325 | 0.0001908 | 0.002374 |
375 | ALCOHOL BIOSYNTHETIC PROCESS | 4 | 111 | 0.0001981 | 0.002459 |
376 | REGULATION OF PEPTIDE SECRETION | 5 | 209 | 0.0002071 | 0.002556 |
377 | LYMPHOCYTE DIFFERENTIATION | 5 | 209 | 0.0002071 | 0.002556 |
378 | POSITIVE REGULATION OF CELL DEVELOPMENT | 7 | 472 | 0.0002083 | 0.002564 |
379 | ORGANOPHOSPHATE CATABOLIC PROCESS | 4 | 113 | 0.0002122 | 0.002598 |
380 | RESPONSE TO MECHANICAL STIMULUS | 5 | 210 | 0.0002118 | 0.002598 |
381 | POSITIVE REGULATION OF PROTEIN SECRETION | 5 | 211 | 0.0002165 | 0.002644 |
382 | SPROUTING ANGIOGENESIS | 3 | 45 | 0.0002178 | 0.002653 |
383 | ESTABLISHMENT OF PROTEIN LOCALIZATION | 12 | 1423 | 0.0002298 | 0.002792 |
384 | PEPTIDYL THREONINE MODIFICATION | 3 | 46 | 0.0002325 | 0.002803 |
385 | INTRASPECIES INTERACTION BETWEEN ORGANISMS | 3 | 46 | 0.0002325 | 0.002803 |
386 | SOCIAL BEHAVIOR | 3 | 46 | 0.0002325 | 0.002803 |
387 | REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT | 4 | 116 | 0.0002346 | 0.002821 |
388 | LEUKOCYTE CHEMOTAXIS | 4 | 117 | 0.0002425 | 0.002908 |
389 | REGULATION OF DNA METABOLIC PROCESS | 6 | 340 | 0.0002433 | 0.00291 |
390 | POSITIVE REGULATION OF CHEMOTAXIS | 4 | 120 | 0.0002671 | 0.003187 |
391 | ESTABLISHMENT OF LOCALIZATION IN CELL | 13 | 1676 | 0.0002731 | 0.00325 |
392 | RESPONSE TO STEROID HORMONE | 7 | 497 | 0.0002852 | 0.003379 |
393 | REGULATED EXOCYTOSIS | 5 | 224 | 0.0002854 | 0.003379 |
394 | ENDOCRINE SYSTEM DEVELOPMENT | 4 | 123 | 0.0002935 | 0.003458 |
395 | RESPONSE TO OXIDATIVE STRESS | 6 | 352 | 0.000293 | 0.003458 |
396 | REGULATION OF CYTOSKELETON ORGANIZATION | 7 | 502 | 0.000303 | 0.00356 |
397 | MONOCARBOXYLIC ACID METABOLIC PROCESS | 7 | 503 | 0.0003067 | 0.003585 |
398 | NUCLEAR TRANSPORT | 6 | 355 | 0.0003066 | 0.003585 |
399 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 5 | 228 | 0.0003096 | 0.00361 |
400 | RESPONSE TO UV | 4 | 126 | 0.0003218 | 0.003734 |
401 | REGULATION OF SYSTEM PROCESS | 7 | 507 | 0.0003217 | 0.003734 |
402 | ESTABLISHMENT OF PROTEIN LOCALIZATION TO ORGANELLE | 6 | 361 | 0.0003353 | 0.003881 |
403 | MUSCLE CELL DEVELOPMENT | 4 | 128 | 0.0003416 | 0.003945 |
404 | NUCLEAR IMPORT | 4 | 129 | 0.0003519 | 0.004053 |
405 | REGULATION OF INSULIN SECRETION INVOLVED IN CELLULAR RESPONSE TO GLUCOSE STIMULUS | 3 | 53 | 0.0003543 | 0.00407 |
406 | POSITIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 2 | 11 | 0.0003592 | 0.004077 |
407 | CHEMICAL HOMEOSTASIS WITHIN A TISSUE | 2 | 11 | 0.0003592 | 0.004077 |
408 | REGULATION OF FEVER GENERATION | 2 | 11 | 0.0003592 | 0.004077 |
409 | CYCLOOXYGENASE PATHWAY | 2 | 11 | 0.0003592 | 0.004077 |
410 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 2 | 11 | 0.0003592 | 0.004077 |
411 | CIRCULATORY SYSTEM PROCESS | 6 | 366 | 0.0003608 | 0.004085 |
412 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 9 | 872 | 0.0003717 | 0.004198 |
413 | POSITIVE REGULATION OF SECRETION | 6 | 370 | 0.0003823 | 0.004307 |
414 | B CELL ACTIVATION | 4 | 132 | 0.000384 | 0.004316 |
415 | POSITIVE REGULATION OF CELL CELL ADHESION | 5 | 243 | 0.0004146 | 0.004648 |
416 | REGULATION OF BROWN FAT CELL DIFFERENTIATION | 2 | 12 | 0.0004304 | 0.004791 |
417 | GLIAL CELL DIFFERENTIATION | 4 | 136 | 0.00043 | 0.004791 |
418 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 2 | 12 | 0.0004304 | 0.004791 |
419 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 5 | 246 | 0.0004385 | 0.004869 |
420 | UNSATURATED FATTY ACID BIOSYNTHETIC PROCESS | 3 | 58 | 0.0004624 | 0.005123 |
421 | RESPONSE TO ORGANOPHOSPHORUS | 4 | 139 | 0.000467 | 0.005149 |
422 | CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 4 | 139 | 0.000467 | 0.005149 |
423 | NON CANONICAL WNT SIGNALING PATHWAY | 4 | 140 | 0.0004798 | 0.005278 |
424 | VASCULOGENESIS | 3 | 59 | 0.0004863 | 0.005324 |
425 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 3 | 59 | 0.0004863 | 0.005324 |
426 | SYSTEM PROCESS | 13 | 1785 | 0.0005036 | 0.005488 |
427 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 8 | 720 | 0.0005026 | 0.005488 |
428 | LIPOXYGENASE PATHWAY | 2 | 13 | 0.0005078 | 0.005507 |
429 | LYMPH VESSEL MORPHOGENESIS | 2 | 13 | 0.0005078 | 0.005507 |
430 | REGULATION OF GLUCOSE IMPORT | 3 | 60 | 0.0005109 | 0.005516 |
431 | MATERNAL PROCESS INVOLVED IN FEMALE PREGNANCY | 3 | 60 | 0.0005109 | 0.005516 |
432 | REGULATION OF RESPIRATORY BURST | 2 | 14 | 0.0005914 | 0.006198 |
433 | VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 2 | 14 | 0.0005914 | 0.006198 |
434 | ARACHIDONIC ACID SECRETION | 2 | 14 | 0.0005914 | 0.006198 |
435 | REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 2 | 14 | 0.0005914 | 0.006198 |
436 | REGULATION OF HORMONE SECRETION | 5 | 262 | 0.0005839 | 0.006198 |
437 | ESTABLISHMENT OF NUCLEUS LOCALIZATION | 2 | 14 | 0.0005914 | 0.006198 |
438 | T CELL MIGRATION | 2 | 14 | 0.0005914 | 0.006198 |
439 | CARDIOLIPIN METABOLIC PROCESS | 2 | 14 | 0.0005914 | 0.006198 |
440 | REGULATION OF PROTEIN KINASE C SIGNALING | 2 | 14 | 0.0005914 | 0.006198 |
441 | POSITIVE REGULATION OF SPROUTING ANGIOGENESIS | 2 | 14 | 0.0005914 | 0.006198 |
442 | ARACHIDONATE TRANSPORT | 2 | 14 | 0.0005914 | 0.006198 |
443 | REGULATION OF MUSCLE ADAPTATION | 3 | 63 | 0.0005897 | 0.006198 |
444 | RESPONSE TO OSMOTIC STRESS | 3 | 63 | 0.0005897 | 0.006198 |
445 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 5 | 264 | 0.0006043 | 0.006304 |
446 | AGING | 5 | 264 | 0.0006043 | 0.006304 |
447 | EMBRYONIC ORGAN DEVELOPMENT | 6 | 406 | 0.0006238 | 0.006493 |
448 | REGULATION OF MUSCLE CELL DIFFERENTIATION | 4 | 152 | 0.0006538 | 0.006776 |
449 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 4 | 152 | 0.0006538 | 0.006776 |
450 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 8 | 750 | 0.0006575 | 0.006799 |
451 | EPITHELIUM DEVELOPMENT | 9 | 945 | 0.0006656 | 0.006867 |
452 | CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 2 | 15 | 0.0006813 | 0.0069 |
453 | REGULATION OF HEAT GENERATION | 2 | 15 | 0.0006813 | 0.0069 |
454 | NEGATIVE REGULATION OF DENDRITE MORPHOGENESIS | 2 | 15 | 0.0006813 | 0.0069 |
455 | POSITIVE REGULATION OF INSULIN SECRETION | 3 | 66 | 0.0006758 | 0.0069 |
456 | RESPONSE TO RADIATION | 6 | 413 | 0.0006821 | 0.0069 |
457 | RESPIRATORY BURST | 2 | 15 | 0.0006813 | 0.0069 |
458 | JAK STAT CASCADE INVOLVED IN GROWTH HORMONE SIGNALING PATHWAY | 2 | 15 | 0.0006813 | 0.0069 |
459 | REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS | 2 | 15 | 0.0006813 | 0.0069 |
460 | POSITIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS | 3 | 66 | 0.0006758 | 0.0069 |
461 | POSITIVE REGULATION OF NEURON DEATH | 3 | 67 | 0.0007062 | 0.007081 |
462 | PROTEIN IMPORT | 4 | 155 | 0.0007035 | 0.007081 |
463 | CELL AGING | 3 | 67 | 0.0007062 | 0.007081 |
464 | REGULATION OF CELL PROJECTION ASSEMBLY | 4 | 155 | 0.0007035 | 0.007081 |
465 | PROTEIN LOCALIZATION TO NUCLEUS | 4 | 156 | 0.0007206 | 0.007211 |
466 | POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 3 | 68 | 0.0007374 | 0.007363 |
467 | RESPONSE TO PURINE CONTAINING COMPOUND | 4 | 158 | 0.0007558 | 0.00753 |
468 | REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 5 | 278 | 0.0007628 | 0.007584 |
469 | POSITIVE REGULATION OF AXONOGENESIS | 3 | 69 | 0.0007695 | 0.007634 |
470 | SECRETION | 7 | 588 | 0.0007777 | 0.007651 |
471 | POSITIVE REGULATION OF TELOMERE CAPPING | 2 | 16 | 0.0007773 | 0.007651 |
472 | POSITIVE REGULATION OF LAMELLIPODIUM ASSEMBLY | 2 | 16 | 0.0007773 | 0.007651 |
473 | POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 2 | 16 | 0.0007773 | 0.007651 |
474 | RESPONSE TO LIGHT STIMULUS | 5 | 280 | 0.0007878 | 0.007733 |
475 | MUSCLE SYSTEM PROCESS | 5 | 282 | 0.0008134 | 0.007967 |
476 | CELL CHEMOTAXIS | 4 | 162 | 0.0008297 | 0.00811 |
477 | POSITIVE REGULATION OF HEMOPOIESIS | 4 | 163 | 0.0008489 | 0.008247 |
478 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 4 | 163 | 0.0008489 | 0.008247 |
479 | VASCULAR PROCESS IN CIRCULATORY SYSTEM | 4 | 163 | 0.0008489 | 0.008247 |
480 | ANATOMICAL STRUCTURE HOMEOSTASIS | 5 | 285 | 0.0008529 | 0.008267 |
481 | MUSCLE STRUCTURE DEVELOPMENT | 6 | 432 | 0.000862 | 0.008338 |
482 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 2 | 17 | 0.0008795 | 0.008386 |
483 | REGULATION OF CHROMATIN BINDING | 2 | 17 | 0.0008795 | 0.008386 |
484 | POSITIVE REGULATION OF FATTY ACID BIOSYNTHETIC PROCESS | 2 | 17 | 0.0008795 | 0.008386 |
485 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 2 | 17 | 0.0008795 | 0.008386 |
486 | NEGATIVE REGULATION OF ANOIKIS | 2 | 17 | 0.0008795 | 0.008386 |
487 | REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 2 | 17 | 0.0008795 | 0.008386 |
488 | REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 2 | 17 | 0.0008795 | 0.008386 |
489 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 9 | 983 | 0.0008816 | 0.008389 |
490 | REGULATION OF DEVELOPMENTAL GROWTH | 5 | 289 | 0.0009078 | 0.008602 |
491 | REGULATION OF ORGAN GROWTH | 3 | 73 | 0.0009068 | 0.008602 |
492 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 4 | 167 | 0.0009291 | 0.008787 |
493 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 3 | 74 | 0.0009434 | 0.008886 |
494 | REGULATION OF ACUTE INFLAMMATORY RESPONSE | 3 | 74 | 0.0009434 | 0.008886 |
495 | REGULATION OF AXONOGENESIS | 4 | 168 | 0.00095 | 0.00893 |
496 | SENSORY PERCEPTION OF PAIN | 3 | 75 | 0.0009809 | 0.009147 |
497 | GRANULOCYTE MIGRATION | 3 | 75 | 0.0009809 | 0.009147 |
498 | CELLULAR GLUCOSE HOMEOSTASIS | 3 | 75 | 0.0009809 | 0.009147 |
499 | MULTI ORGANISM BEHAVIOR | 3 | 75 | 0.0009809 | 0.009147 |
500 | GLUCOSE HOMEOSTASIS | 4 | 170 | 0.0009926 | 0.009219 |
501 | CARBOHYDRATE HOMEOSTASIS | 4 | 170 | 0.0009926 | 0.009219 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | PHOSPHOLIPASE A2 ACTIVITY | 9 | 31 | 5.046e-17 | 4.688e-14 |
2 | KINASE ACTIVITY | 21 | 842 | 5.625e-16 | 2.159e-13 |
3 | PHOSPHOLIPASE ACTIVITY | 11 | 94 | 6.971e-16 | 2.159e-13 |
4 | LIPASE ACTIVITY | 11 | 117 | 8.388e-15 | 1.948e-12 |
5 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 21 | 992 | 1.45e-14 | 2.694e-12 |
6 | RIBONUCLEOTIDE BINDING | 25 | 1860 | 5.551e-13 | 8.595e-11 |
7 | RECEPTOR SIGNALING PROTEIN ACTIVITY | 10 | 172 | 1.97e-11 | 2.615e-09 |
8 | PROTEIN KINASE ACTIVITY | 15 | 640 | 4.804e-11 | 5.579e-09 |
9 | CARBOXYLIC ESTER HYDROLASE ACTIVITY | 9 | 135 | 6.393e-11 | 6.599e-09 |
10 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 13 | 445 | 7.942e-11 | 7.378e-09 |
11 | MAP KINASE ACTIVITY | 5 | 14 | 1.918e-10 | 1.62e-08 |
12 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 7 | 70 | 5.583e-10 | 4.322e-08 |
13 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 6 | 43 | 1.299e-09 | 9.282e-08 |
14 | HYDROLASE ACTIVITY ACTING ON ESTER BONDS | 14 | 739 | 3.761e-09 | 2.268e-07 |
15 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 6 | 51 | 3.777e-09 | 2.268e-07 |
16 | RECEPTOR SIGNALING PROTEIN SERINE THREONINE KINASE ACTIVITY | 7 | 92 | 3.907e-09 | 2.268e-07 |
17 | ENZYME BINDING | 20 | 1737 | 4.455e-09 | 2.434e-07 |
18 | MAP KINASE KINASE ACTIVITY | 4 | 12 | 1.98e-08 | 1.022e-06 |
19 | ADENYL NUCLEOTIDE BINDING | 18 | 1514 | 2.139e-08 | 1.046e-06 |
20 | KINASE BINDING | 12 | 606 | 3.663e-08 | 1.702e-06 |
21 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 4 | 16 | 7.224e-08 | 3.196e-06 |
22 | PHOSPHATASE BINDING | 7 | 162 | 1.979e-07 | 8.355e-06 |
23 | KINASE REGULATOR ACTIVITY | 7 | 186 | 5.049e-07 | 2.039e-05 |
24 | INSULIN RECEPTOR SUBSTRATE BINDING | 3 | 11 | 2.695e-06 | 0.0001043 |
25 | PROTEIN SERINE THREONINE TYROSINE KINASE ACTIVITY | 4 | 39 | 3.124e-06 | 0.0001161 |
26 | CALCIUM DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 12 | 3.587e-06 | 0.0001282 |
27 | CALMODULIN BINDING | 6 | 179 | 6.838e-06 | 0.0002353 |
28 | PROTEIN PHOSPHATASE BINDING | 5 | 120 | 1.483e-05 | 0.0004922 |
29 | SIGNAL TRANSDUCER ACTIVITY | 15 | 1731 | 2.22e-05 | 0.000711 |
30 | CALCIUM ION BINDING | 9 | 697 | 6.919e-05 | 0.002142 |
31 | MOLECULAR FUNCTION REGULATOR | 12 | 1353 | 0.0001433 | 0.004294 |
32 | SCAFFOLD PROTEIN BINDING | 3 | 45 | 0.0002178 | 0.006322 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 7 | 20 | 3.984e-14 | 2.327e-11 |
2 | EXTRINSIC COMPONENT OF MEMBRANE | 10 | 252 | 8.389e-10 | 2.449e-07 |
3 | CELL SUBSTRATE JUNCTION | 10 | 398 | 6.535e-08 | 1.272e-05 |
4 | ANCHORING JUNCTION | 10 | 489 | 4.388e-07 | 6.406e-05 |
5 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 7 | 237 | 2.552e-06 | 0.0002981 |
6 | CELL JUNCTION | 13 | 1151 | 5.499e-06 | 0.0004588 |
7 | LAMELLIPODIUM | 6 | 172 | 5.438e-06 | 0.0004588 |
8 | GOLGI APPARATUS | 14 | 1445 | 1.292e-05 | 0.0009432 |
9 | MAST CELL GRANULE | 3 | 21 | 2.133e-05 | 0.001384 |
10 | CELL LEADING EDGE | 7 | 350 | 3.219e-05 | 0.00188 |
11 | PLASMA MEMBRANE RAFT | 4 | 86 | 7.37e-05 | 0.003913 |
12 | CYTOSKELETON | 15 | 1967 | 9.787e-05 | 0.004438 |
13 | MEMBRANE MICRODOMAIN | 6 | 288 | 9.879e-05 | 0.004438 |
14 | EARLY ENDOSOME | 6 | 301 | 0.0001258 | 0.005247 |
15 | VACUOLE | 11 | 1180 | 0.0001854 | 0.007219 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04370_VEGF_signaling_pathway | 52 | 76 | 7.211e-137 | 1.298e-134 | |
2 | hsa04664_Fc_epsilon_RI_signaling_pathway | 34 | 79 | 1.837e-72 | 1.653e-70 | |
3 | hsa04014_Ras_signaling_pathway | 33 | 236 | 1.462e-51 | 8.773e-50 | |
4 | hsa04662_B_cell_receptor_signaling_pathway | 25 | 75 | 1.104e-48 | 4.969e-47 | |
5 | hsa04660_T_cell_receptor_signaling_pathway | 26 | 108 | 1.888e-46 | 6.797e-45 | |
6 | hsa04010_MAPK_signaling_pathway | 31 | 268 | 2.209e-45 | 6.628e-44 | |
7 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 26 | 136 | 1.507e-43 | 3.875e-42 | |
8 | hsa04912_GnRH_signaling_pathway | 23 | 101 | 3.18e-40 | 7.156e-39 | |
9 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 22 | 95 | 1.357e-38 | 2.715e-37 | |
10 | hsa04722_Neurotrophin_signaling_pathway | 23 | 127 | 1.078e-37 | 1.94e-36 | |
11 | hsa04012_ErbB_signaling_pathway | 21 | 87 | 3.248e-37 | 5.315e-36 | |
12 | hsa04730_Long.term_depression | 19 | 70 | 1.047e-34 | 1.571e-33 | |
13 | hsa04510_Focal_adhesion | 22 | 200 | 6.383e-31 | 8.839e-30 | |
14 | hsa04670_Leukocyte_transendothelial_migration | 19 | 117 | 5.302e-30 | 6.817e-29 | |
15 | hsa04380_Osteoclast_differentiation | 19 | 128 | 3.305e-29 | 3.966e-28 | |
16 | hsa04062_Chemokine_signaling_pathway | 20 | 189 | 1.117e-27 | 1.257e-26 | |
17 | hsa04151_PI3K_AKT_signaling_pathway | 23 | 351 | 4.485e-27 | 4.748e-26 | |
18 | hsa04620_Toll.like_receptor_signaling_pathway | 16 | 102 | 5.454e-25 | 5.454e-24 | |
19 | hsa04810_Regulation_of_actin_cytoskeleton | 19 | 214 | 8.992e-25 | 8.518e-24 | |
20 | hsa04914_Progesterone.mediated_oocyte_maturation | 15 | 87 | 4.175e-24 | 3.758e-23 | |
21 | hsa04270_Vascular_smooth_muscle_contraction | 16 | 116 | 4.879e-24 | 4.182e-23 | |
22 | hsa04910_Insulin_signaling_pathway | 16 | 138 | 9.056e-23 | 7.409e-22 | |
23 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 12 | 42 | 2.533e-22 | 1.982e-21 | |
24 | hsa00592_alpha.Linolenic_acid_metabolism | 10 | 20 | 1.018e-21 | 7.638e-21 | |
25 | hsa04360_Axon_guidance | 15 | 130 | 2.488e-21 | 1.791e-20 | |
26 | hsa00591_Linoleic_acid_metabolism | 10 | 30 | 1.625e-19 | 1.125e-18 | |
27 | hsa04972_Pancreatic_secretion | 13 | 101 | 3.37e-19 | 2.247e-18 | |
28 | hsa04150_mTOR_signaling_pathway | 11 | 52 | 6.601e-19 | 4.244e-18 | |
29 | hsa00565_Ether_lipid_metabolism | 10 | 36 | 1.359e-18 | 8.435e-18 | |
30 | hsa00590_Arachidonic_acid_metabolism | 11 | 59 | 3.018e-18 | 1.811e-17 | |
31 | hsa04210_Apoptosis | 12 | 89 | 4.984e-18 | 2.894e-17 | |
32 | hsa04975_Fat_digestion_and_absorption | 10 | 46 | 2.138e-17 | 1.203e-16 | |
33 | hsa04720_Long.term_potentiation | 11 | 70 | 2.286e-17 | 1.247e-16 | |
34 | hsa04070_Phosphatidylinositol_signaling_system | 11 | 78 | 8.094e-17 | 4.285e-16 | |
35 | hsa04973_Carbohydrate_digestion_and_absorption | 9 | 44 | 1.73e-15 | 8.899e-15 | |
36 | hsa00564_Glycerophospholipid_metabolism | 10 | 80 | 8.091e-15 | 4.046e-14 | |
37 | hsa04540_Gap_junction | 9 | 90 | 1.577e-12 | 7.67e-12 | |
38 | hsa04916_Melanogenesis | 9 | 101 | 4.563e-12 | 2.162e-11 | |
39 | hsa04310_Wnt_signaling_pathway | 10 | 151 | 5.372e-12 | 2.479e-11 | |
40 | hsa04630_Jak.STAT_signaling_pathway | 8 | 155 | 6.118e-09 | 2.753e-08 | |
41 | hsa00562_Inositol_phosphate_metabolism | 6 | 57 | 7.521e-09 | 3.302e-08 | |
42 | hsa04020_Calcium_signaling_pathway | 8 | 177 | 1.734e-08 | 7.431e-08 | |
43 | hsa04530_Tight_junction | 7 | 133 | 5.116e-08 | 2.142e-07 | |
44 | hsa04621_NOD.like_receptor_signaling_pathway | 5 | 59 | 4.391e-07 | 1.796e-06 | |
45 | hsa04320_Dorso.ventral_axis_formation | 4 | 25 | 4.935e-07 | 1.974e-06 | |
46 | hsa04520_Adherens_junction | 5 | 73 | 1.282e-06 | 5.016e-06 | |
47 | hsa04114_Oocyte_meiosis | 5 | 114 | 1.156e-05 | 4.428e-05 | |
48 | hsa04622_RIG.I.like_receptor_signaling_pathway | 3 | 71 | 0.0008364 | 0.003136 | |
49 | hsa04144_Endocytosis | 3 | 203 | 0.01581 | 0.05722 | |
50 | hsa04971_Gastric_acid_secretion | 2 | 74 | 0.01589 | 0.05722 | |
51 | hsa04350_TGF.beta_signaling_pathway | 2 | 85 | 0.02063 | 0.07281 | |
52 | hsa04970_Salivary_secretion | 2 | 89 | 0.02248 | 0.07782 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | MAGI2-AS3 |
hsa-miR-149-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-429;hsa-miR-455-5p;hsa-miR-590-3p | 10 | KDR | Sponge network | -0.939 | 4.0E-5 | -0.064 | 0.72302 | 0.661 |
2 | MAGI2-AS3 |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-29b-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-424-5p;hsa-miR-429;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 25 | PIK3R1 | Sponge network | -0.939 | 4.0E-5 | -1.219 | 0 | 0.589 |
3 | MAGI2-AS3 |
hsa-miR-130b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-205-3p;hsa-miR-222-3p;hsa-miR-2355-3p;hsa-miR-2355-5p;hsa-miR-26b-3p;hsa-miR-27b-5p;hsa-miR-29a-5p;hsa-miR-30c-5p;hsa-miR-320a;hsa-miR-320b;hsa-miR-33a-3p;hsa-miR-3607-3p;hsa-miR-3613-5p;hsa-miR-7-1-3p | 20 | NFATC2 | Sponge network | -0.939 | 4.0E-5 | -1.255 | 0.00017 | 0.524 |
4 | RP11-193H5.1 |
hsa-miR-130b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-2355-5p;hsa-miR-29a-5p;hsa-miR-320a;hsa-miR-7-1-3p | 10 | NFATC2 | Sponge network | -0.426 | 0.01062 | -1.255 | 0.00017 | 0.518 |
5 | RP11-815I9.4 |
hsa-miR-103a-3p;hsa-miR-148b-5p;hsa-miR-15a-5p;hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-29b-3p;hsa-miR-30c-5p;hsa-miR-320a;hsa-miR-361-3p;hsa-miR-576-5p;hsa-miR-590-5p;hsa-miR-664a-3p | 14 | NFAT5 | Sponge network | 0.004 | 0.98116 | -0.144 | 0.16169 | 0.517 |
6 | RP11-193H5.1 |
hsa-miR-130a-3p;hsa-miR-16-2-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-24-1-5p;hsa-miR-29a-5p;hsa-miR-29b-2-5p;hsa-miR-29b-3p;hsa-miR-320a;hsa-miR-362-5p;hsa-miR-374a-3p;hsa-miR-501-5p | 12 | MAPK1 | Sponge network | -0.426 | 0.01062 | -0.025 | 0.75566 | 0.487 |
7 | RP11-594N15.3 |
hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-320b;hsa-miR-93-5p | 15 | PIK3R1 | Sponge network | -2.86 | 0 | -1.219 | 0 | 0.483 |
8 | SNHG14 | hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-455-3p;hsa-miR-584-5p;hsa-miR-589-3p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -1.125 | 0.0001 | -1.219 | 0 | 0.482 |
9 | AC007743.1 |
hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-424-5p;hsa-miR-584-5p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p | 13 | PIK3R1 | Sponge network | -1.053 | 0.00923 | -1.219 | 0 | 0.478 |
10 | CTA-221G9.11 | hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-450b-5p;hsa-miR-629-3p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -2.198 | 0 | -1.219 | 0 | 0.477 |
11 | RP1-193H18.2 | hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-455-3p;hsa-miR-584-5p;hsa-miR-589-3p;hsa-miR-96-5p | 11 | PIK3R1 | Sponge network | -1.539 | 0 | -1.219 | 0 | 0.476 |
12 | AC108142.1 | hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-27b-5p;hsa-miR-29b-2-5p;hsa-miR-30d-3p;hsa-miR-30e-3p;hsa-miR-362-5p;hsa-miR-374a-5p;hsa-miR-429;hsa-miR-532-3p | 10 | PRKCA | Sponge network | 2.31 | 0 | 0.318 | 0.04622 | 0.474 |
13 | RP11-193H5.1 |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-130b-5p;hsa-miR-148b-5p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-25-3p;hsa-miR-29b-3p;hsa-miR-320a;hsa-miR-362-5p;hsa-miR-374a-3p;hsa-miR-500a-5p;hsa-miR-576-5p | 15 | NFAT5 | Sponge network | -0.426 | 0.01062 | -0.144 | 0.16169 | 0.472 |
14 | RP11-400K9.4 |
hsa-miR-103a-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-20a-5p;hsa-miR-324-3p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -0.304 | 0.38627 | -1.219 | 0 | 0.469 |
15 | PWAR6 | hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-455-3p;hsa-miR-589-3p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -1.629 | 0 | -1.219 | 0 | 0.466 |
16 | RP11-815I9.4 |
hsa-miR-103a-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-29b-3p;hsa-miR-320a;hsa-miR-589-3p;hsa-miR-590-5p | 11 | PIK3R1 | Sponge network | 0.004 | 0.98116 | -1.219 | 0 | 0.464 |
17 | SH3RF3-AS1 |
hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-205-3p;hsa-miR-222-3p;hsa-miR-2355-5p;hsa-miR-26b-3p;hsa-miR-29a-5p;hsa-miR-30b-5p;hsa-miR-30c-5p;hsa-miR-320a;hsa-miR-320b;hsa-miR-7-1-3p | 15 | NFATC2 | Sponge network | -0.175 | 0.58985 | -1.255 | 0.00017 | 0.463 |
18 | RP11-284N8.3 | hsa-miR-103a-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-455-3p;hsa-miR-590-5p;hsa-miR-93-5p;hsa-miR-96-5p | 12 | PIK3R1 | Sponge network | 0.003 | 0.99478 | -1.219 | 0 | 0.457 |
19 | BHLHE40-AS1 |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-450b-5p;hsa-miR-590-5p;hsa-miR-96-5p | 10 | PIK3R1 | Sponge network | -0.932 | 0 | -1.219 | 0 | 0.438 |
20 | SH3RF3-AS1 |
hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-222-3p;hsa-miR-29b-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-590-5p | 13 | PIK3R1 | Sponge network | -0.175 | 0.58985 | -1.219 | 0 | 0.435 |
21 | ZNF667-AS1 | hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-424-5p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-96-5p | 14 | PIK3R1 | Sponge network | -1.395 | 0 | -1.219 | 0 | 0.434 |
22 | CTD-2015G9.2 |
hsa-miR-130b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-222-3p;hsa-miR-2355-3p;hsa-miR-2355-5p;hsa-miR-7-1-3p | 10 | NFATC2 | Sponge network | -3.112 | 5.0E-5 | -1.255 | 0.00017 | 0.432 |
23 | RP11-774O3.3 |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-320b;hsa-miR-324-3p;hsa-miR-424-5p;hsa-miR-589-3p | 15 | PIK3R1 | Sponge network | -1.712 | 0 | -1.219 | 0 | 0.415 |
24 | AF127936.7 |
hsa-miR-17-3p;hsa-miR-181c-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-27b-5p;hsa-miR-29b-2-5p;hsa-miR-30d-3p;hsa-miR-30e-3p;hsa-miR-362-5p;hsa-miR-374a-5p;hsa-miR-532-3p | 12 | PRKCA | Sponge network | 0.453 | 0.00811 | 0.318 | 0.04622 | 0.412 |
25 | SH3RF3-AS1 |
hsa-miR-103a-2-5p;hsa-miR-183-5p;hsa-miR-186-5p;hsa-miR-1976;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-24-2-5p;hsa-miR-339-5p;hsa-miR-505-5p | 10 | PRKCA | Sponge network | -0.175 | 0.58985 | 0.318 | 0.04622 | 0.404 |
26 | RP11-166D19.1 |
hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-205-3p;hsa-miR-222-3p;hsa-miR-2355-3p;hsa-miR-2355-5p;hsa-miR-26b-3p;hsa-miR-27b-5p;hsa-miR-33a-3p;hsa-miR-3613-5p;hsa-miR-484;hsa-miR-7-1-3p | 14 | NFATC2 | Sponge network | -0.882 | 5.0E-5 | -1.255 | 0.00017 | 0.403 |
27 | RP11-166D19.1 |
hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-324-3p;hsa-miR-429;hsa-miR-455-3p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-96-5p | 19 | PIK3R1 | Sponge network | -0.882 | 5.0E-5 | -1.219 | 0 | 0.401 |
28 | MAGI2-AS3 |
hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-205-3p;hsa-miR-23a-3p;hsa-miR-24-3p;hsa-miR-27a-3p;hsa-miR-429;hsa-miR-452-3p;hsa-miR-589-3p;hsa-miR-944 | 10 | PRKCB | Sponge network | -0.939 | 4.0E-5 | -0.01 | 0.96606 | 0.401 |
29 | CTD-2015G9.2 |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-450b-5p;hsa-miR-589-3p;hsa-miR-93-5p | 16 | PIK3R1 | Sponge network | -3.112 | 5.0E-5 | -1.219 | 0 | 0.397 |
30 | RP4-798P15.3 |
hsa-miR-103a-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-455-3p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-96-5p | 14 | PIK3R1 | Sponge network | -1.213 | 0.00098 | -1.219 | 0 | 0.393 |
31 | AC007743.1 |
hsa-miR-16-2-3p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-205-3p;hsa-miR-222-3p;hsa-miR-2355-3p;hsa-miR-2355-5p;hsa-miR-29a-5p;hsa-miR-7-1-3p | 10 | NFATC2 | Sponge network | -1.053 | 0.00923 | -1.255 | 0.00017 | 0.386 |
32 | CTD-2135D7.5 | hsa-miR-103a-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-185-5p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-450b-5p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -2.579 | 0.0001 | -1.219 | 0 | 0.379 |
33 | LINC00900 |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-424-5p;hsa-miR-455-3p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-93-5p | 19 | PIK3R1 | Sponge network | -1.803 | 0 | -1.219 | 0 | 0.373 |
34 | AC003090.1 |
hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-424-5p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 18 | PIK3R1 | Sponge network | -4.323 | 0 | -1.219 | 0 | 0.369 |
35 | RP11-757G1.6 | hsa-miR-103a-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-424-5p;hsa-miR-589-3p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -1.346 | 0.00088 | -1.219 | 0 | 0.367 |
36 | CTD-2015G9.2 |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-130b-5p;hsa-miR-148b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-361-3p;hsa-miR-362-5p;hsa-miR-500a-3p;hsa-miR-576-5p;hsa-miR-93-5p | 17 | NFAT5 | Sponge network | -3.112 | 5.0E-5 | -0.144 | 0.16169 | 0.362 |
37 | RP4-798P15.3 |
hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-205-3p;hsa-miR-222-3p;hsa-miR-2355-3p;hsa-miR-2355-5p;hsa-miR-29a-5p;hsa-miR-31-3p;hsa-miR-484;hsa-miR-7-1-3p | 13 | NFATC2 | Sponge network | -1.213 | 0.00098 | -1.255 | 0.00017 | 0.362 |
38 | LINC00702 |
hsa-miR-17-3p;hsa-miR-183-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-27b-5p;hsa-miR-29b-2-5p;hsa-miR-30d-3p;hsa-miR-339-5p;hsa-miR-500a-5p;hsa-miR-532-3p;hsa-miR-590-3p;hsa-miR-92a-3p;hsa-miR-93-3p | 14 | PRKCA | Sponge network | -0.573 | 0.0699 | 0.318 | 0.04622 | 0.359 |
39 | RP11-594N15.3 |
hsa-miR-130b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-205-3p;hsa-miR-222-3p;hsa-miR-2355-3p;hsa-miR-2355-5p;hsa-miR-27b-5p;hsa-miR-320b;hsa-miR-3607-3p;hsa-miR-484 | 14 | NFATC2 | Sponge network | -2.86 | 0 | -1.255 | 0.00017 | 0.353 |
40 | MAGI2-AS3 |
hsa-miR-103a-2-5p;hsa-miR-17-3p;hsa-miR-183-5p;hsa-miR-186-5p;hsa-miR-1976;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-24-2-5p;hsa-miR-27b-5p;hsa-miR-339-5p;hsa-miR-3607-3p;hsa-miR-362-5p;hsa-miR-429;hsa-miR-500a-5p;hsa-miR-501-5p;hsa-miR-532-3p;hsa-miR-590-3p;hsa-miR-92a-3p;hsa-miR-93-3p | 20 | PRKCA | Sponge network | -0.939 | 4.0E-5 | 0.318 | 0.04622 | 0.351 |
41 | EMX2OS |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-29b-3p;hsa-miR-324-3p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 22 | PIK3R1 | Sponge network | -1.459 | 1.0E-5 | -1.219 | 0 | 0.349 |
42 | MIR497HG |
hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-455-3p;hsa-miR-584-5p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-96-5p | 13 | PIK3R1 | Sponge network | -1.263 | 0.00248 | -1.219 | 0 | 0.343 |
43 | LINC00284 |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-424-5p;hsa-miR-455-3p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 17 | PIK3R1 | Sponge network | -4.159 | 0 | -1.219 | 0 | 0.333 |
44 | DNM3OS | hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-224-3p;hsa-miR-429;hsa-miR-590-5p;hsa-miR-96-5p | 11 | PIK3R1 | Sponge network | 0.932 | 0.00442 | -1.219 | 0 | 0.328 |
45 | AF127936.7 |
hsa-miR-155-5p;hsa-miR-15b-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-181c-5p;hsa-miR-25-3p;hsa-miR-27b-5p;hsa-miR-320a;hsa-miR-361-3p;hsa-miR-362-5p | 11 | NFAT5 | Sponge network | 0.453 | 0.00811 | -0.144 | 0.16169 | 0.321 |
46 | DLGAP1-AS5 | hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-589-3p | 10 | PIK3R1 | Sponge network | -6.207 | 0 | -1.219 | 0 | 0.315 |
47 | RP11-58E21.3 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-130b-5p;hsa-miR-181c-5p;hsa-miR-194-5p;hsa-miR-25-3p;hsa-miR-362-5p;hsa-miR-500a-3p;hsa-miR-582-3p;hsa-miR-93-5p | 10 | NFAT5 | Sponge network | 0.445 | 0.04375 | -0.144 | 0.16169 | 0.308 |
48 | TPTEP1 |
hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-424-5p;hsa-miR-455-3p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | -2.193 | 0 | -1.219 | 0 | 0.308 |
49 | LINC00957 | hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-455-3p | 10 | PIK3R1 | Sponge network | -0.677 | 2.0E-5 | -1.219 | 0 | 0.306 |
50 | RP11-193H5.1 |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-320a | 11 | PIK3R1 | Sponge network | -0.426 | 0.01062 | -1.219 | 0 | 0.297 |
51 | LINC00675 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-130b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-1-3p;hsa-miR-181a-5p;hsa-miR-194-5p;hsa-miR-21-5p;hsa-miR-25-3p | 10 | NFAT5 | Sponge network | -4.584 | 0 | -0.144 | 0.16169 | 0.295 |
52 | LINC00702 |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-324-3p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 21 | PIK3R1 | Sponge network | -0.573 | 0.0699 | -1.219 | 0 | 0.294 |
53 | EMX2OS |
hsa-miR-130b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-205-3p;hsa-miR-222-3p;hsa-miR-2355-3p;hsa-miR-2355-5p;hsa-miR-26b-3p;hsa-miR-27b-5p;hsa-miR-29a-5p;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-3607-3p;hsa-miR-484;hsa-miR-7-1-3p;hsa-miR-9-5p | 19 | NFATC2 | Sponge network | -1.459 | 1.0E-5 | -1.255 | 0.00017 | 0.292 |
54 | RP4-798P15.3 |
hsa-miR-103a-3p;hsa-miR-148b-5p;hsa-miR-155-5p;hsa-miR-15a-5p;hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-362-5p;hsa-miR-500a-3p;hsa-miR-500a-5p;hsa-miR-576-5p;hsa-miR-590-5p | 14 | NFAT5 | Sponge network | -1.213 | 0.00098 | -0.144 | 0.16169 | 0.29 |
55 | MIR22HG |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-130b-5p;hsa-miR-148b-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-181c-5p;hsa-miR-186-5p;hsa-miR-194-5p;hsa-miR-20a-5p;hsa-miR-25-3p;hsa-miR-582-5p;hsa-miR-590-5p;hsa-miR-92a-3p;hsa-miR-93-5p | 17 | NFAT5 | Sponge network | -0.601 | 4.0E-5 | -0.144 | 0.16169 | 0.288 |
56 | RP11-166D19.1 |
hsa-miR-103a-2-5p;hsa-miR-17-3p;hsa-miR-183-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-24-2-5p;hsa-miR-27b-5p;hsa-miR-339-5p;hsa-miR-429;hsa-miR-532-3p;hsa-miR-92a-3p;hsa-miR-93-3p | 13 | PRKCA | Sponge network | -0.882 | 5.0E-5 | 0.318 | 0.04622 | 0.285 |
57 | RP11-193H5.1 |
hsa-miR-103a-2-5p;hsa-miR-186-5p;hsa-miR-24-2-5p;hsa-miR-29b-2-5p;hsa-miR-339-5p;hsa-miR-362-5p;hsa-miR-500a-5p;hsa-miR-501-5p;hsa-miR-505-5p;hsa-miR-93-3p | 10 | PRKCA | Sponge network | -0.426 | 0.01062 | 0.318 | 0.04622 | 0.281 |
58 | CASC15 |
hsa-miR-17-3p;hsa-miR-1976;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-27b-5p;hsa-miR-29b-2-5p;hsa-miR-30d-3p;hsa-miR-30e-3p;hsa-miR-429;hsa-miR-590-3p | 10 | PRKCA | Sponge network | 1.485 | 0 | 0.318 | 0.04622 | 0.269 |
59 | CTC-297N7.7 | hsa-miR-103a-3p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-224-3p;hsa-miR-589-3p;hsa-miR-629-3p;hsa-miR-96-5p | 11 | PIK3R1 | Sponge network | -1.666 | 0.01558 | -1.219 | 0 | 0.267 |
60 | CTD-2554C21.3 | hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-455-3p;hsa-miR-629-3p | 10 | PIK3R1 | Sponge network | -2.118 | 6.0E-5 | -1.219 | 0 | 0.267 |
61 | CTD-2008P7.9 |
hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-130b-5p;hsa-miR-148b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-500a-5p;hsa-miR-576-5p | 16 | NFAT5 | Sponge network | -1.202 | 0.00093 | -0.144 | 0.16169 | 0.254 |